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ABSTRACT 
 
The presence of endotoxin in animals and humans triggers a sequence of acute phase 
responses, which include the synthesis and release of pro-inflammatory cytokines from 
immune cells, followed by the development of various symptoms of sickness including 
fever and an array of behavioural responses, commonly referred to as sickness 
behaviours.  Most experimental investigations examining the mechanisms mediating 
fever and sickness behaviour responses have used purified lipopolysaccharide (LPS), the 
glycolipid pyrogenic moiety of the Gram-negative bacterial membrane, to trigger the 
innate immune system.  Results obtained from studies using specific antagonists to block 
the action of cytokines synthesized following systemic administration of LPS, have 
uncovered important roles for pro-inflammatory cytokines, such as interleukin (IL)-1β, 
IL-6, tumour necrosis factor-alpha (TNF-α) and leptin, in mediating fever.  Although it 
has been shown that administration of pro-inflammatory cytokines can induce sickness 
behaviour in experimental animals, no clear role has been identified for these cytokines 
as endogenous mediators of sickness behaviours induced following LPS administration. 
 
Using rats as experimental animals and endogenous cytokine antagonism, I therefore 
investigated whether endogenously released IL-1β, IL-6, TNF-α and leptin are 
physiologically active not only in the generation of fever, but also in the generation of 
two specific sickness behaviours, lethargy and anorexia, induced by subcutaneous (s.c.) 
administration of LPS.  Lethargy, anorexia and fever were measured as changes in 
voluntary wheel-running, food intake and body temperature respectively.  I antagonized 
 vii 
the biological action of these cytokines in the periphery following s.c. administration of 
LPS by injecting rats intraperitoneally (i.p.) with specific anti-rat sera to one of the 
following: TNF-α, IL-1β, IL-6 or leptin.  Peripherally-released leptin appeared to be an 
important mediator of both fever and anorexia, as the presence of leptin antibodies in the 
circulation abolished both the anorexia and fever induced by s.c. administration of LPS.  
In contrast though, whereas the presence of IL-6 antibodies in the circulation abolished 
the LPS-induced fever, suppression of voluntary activity was reversed by the presence of 
IL-6 antibodies only to the extent of 27%, and appetite also was not returned to normal 
levels in the presence of IL-6 antibodies.  Thus, IL-6 may be an essential component of 
LPS-induced fever, but an additional factor or factors, possibly working in parallel with 
IL-6, may be required to mediate the lethargy and anorexia induced by s.c. administration 
of LPS.  Injecting rats i.p. with TNF-α antiserum or IL-1β antiserum had no effect on 
LPS-induced lethargy and LPS-anorexia, indicating that if these cytokines are working 
with peripherally-released IL-6 to induce sickness behaviour, it is likely due to their 
synthesis in the brain. 
 
Injecting species-homologous rat IL-1β and IL-6 into the brains of conscious rats, I aimed 
to identify whether either of these two cytokines can act within the brain to induce 
lethargy and anorexia in the absence of an infection.  Intracerebroventricular (i.c.v.) 
administration of either IL-1β or IL-6 before the night-time active period decreased 
voluntary activity in the rats in a dose-dependent fashion, whereas only IL-1β decreased 
food intake and body mass of the rats.   It is possible therefore, that increased levels of 
IL-1β in the brain may be working in parallel with IL-6 released in the periphery to 
induce lethargy and anorexia following s.c. administration of LPS. 
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Thus I antagonized the biological action of these cytokines endogenously by 
administering species-specific antiserum to IL-6 (IL-6AS) i.p., and a caspase-1 inhibitor, 
which prevents the cleavage of pro-IL-1β to biologically active IL-1β, i.c.v. and 
monitored the symptoms of sickness induced by LPS until they ceased, so as to determine 
the cytokine involvement not only in the induction of these responses, but also in the 
resolution of these responses.  Pre-treating rats with either IL-6AS i.p. or a caspase-1 
inhibitor i.c.v. attenuated the magnitude and the duration of the anorexia and lethargy 
induced by LPS administration.  LPS-induced fever was completely abolished in rats pre-
treated i.p. with IL-6AS, while it was only partially attenuated in rats pre-treated i.c.v. 
with a caspase-1 inhibitor.   
 
In conclusion, there appears to be some distinct differences in the cytokine-mechanisms 
regulating fever and sickness behaviours induced by LPS.  Identifying the physiological 
mechanisms mediating fever and sickness behaviours during illness may provide 
clinicians with more insight into managing not only the thermal, but also the non-thermal 
responses to infections, responses which may become detrimental to the host if they 
continue for a prolonged period.  My observation that reducing either IL-6 in the 
circulation or IL-1β in the brain significantly enhances the resolution of anorexia and 
lethargy, but does not completely prevent them from occurring, appears to indicate that 
while individual cytokines are possible targets for therapies aimed at alleviating these 
sickness responses in patients with bacterial infections, to abolish them multiple 
cytokines may need to be targeted. 
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PREFACE 
 
Having cared for a sick child or animal caregivers recognize that most often it is the 
dramatic changes in behaviour that provide signs that their child or pet is ill.  Sick 
humans and animals often are “feverish”; they do not feel like eating food, have an 
increased sensitivity to pain and lose interest in their physical and social environments.  
They feel fatigued and are reluctant to engage in their normal daily activities.  Their sleep 
is also often fragmented and they develop a depressed mood.  Each of these sickness 
symptoms negatively impact on the sick individuals’ quality of life and are extremely 
uncomfortable, which is often what necessitates medical intervention.   
 
The discovery that these non-specific behavioural symptoms are not only particular to 
patients with a “common cold” or flu, but in fact also appear to occur in patients with 
some of the most harmful, costly and debilitating diseases currently experienced in the 
Western World: coronary heart disease, cancer, obesity, type II diabetes and 
neurodegenerative disorders associated with aging, has enhanced the effort of basic 
scientists and clinicians to identify the pathophysiological mechanisms causing these 
behavioural symptoms, with the view to developing treatment strategies aimed 
specifically at managing them. 
 
A major breakthrough in identifying the possible mechanisms involved in mediating 
illness-induced behavioural symptoms arose serendipitously from clinical studies in 
which proteins important for immune function, known as pro-inflammatory cytokines, 
 xxiv
were used in the treatment of the immunosuppression present in cancer patients.  
Injecting cancer patients with these cytokines produced a suite of sickness responses, 
including fever, fatigue, malaise, headaches, anorexia and depression, similar to those 
noted during infection.  From these clinical studies showing that pro-inflammatory 
cytokines, molecules produced by immune cells of the host in response to a variety of 
disease-causing pathogens, can induce dramatic changes in behaviour resembling those 
seen during infection, the question has arisen as to whether these proteins are likely 
mediators of sickness responses.  The use of agents that specifically block the synthesis 
of cytokines in animal models of simulated Gram-negative bacterial infection has 
successfully been used to identify the involvement of cytokines in mediating fever 
induced by a variety of disease-causing pathogens.  In contrast to the important role 
established for cytokines as endogenous mediators of fever, no clear picture has emerged 
as yet regarding their involvement as endogenous mediators of anorexia and lethargy, two 
brain-controlled sickness behaviours, also known to be induced during an infection. 
 
The main aim of this thesis was therefore to systematically investigate the involvement of 
four principal cytokines, TNF-α, IL-1β, IL-6 and leptin in mediating not only fever, but 
two specific behavioural symptoms of sickness, namely lethargy and anorexia, in an 
animal model of simulated Gram-negative bacterial infection.  As sickness and recovery 
processes are ultimately governed/controlled by the brain, a secondary aim of this thesis 
was to investigate the action of cytokines within the brain, on voluntary activity and food 
intake in the absence of a simulated infection. 
 
 xxv
In Chapter 1 I review the studies which have thus far examined the contribution of the 
four principal pro-inflammatory cytokines, IL-1β, IL-6, TNF-α and leptin, in mediating 
fever and sickness behaviours, specifically anorexia and lethargy, induced by peripheral 
administration of LPS.  Chapters 2-4 contain publications that form the main body of the 
thesis.  In Chapter 2 I administered species-and cytokine-specific antisera to examine 
whether peripherally-released cytokines, IL-1β, IL-6, TNF-α and leptin are 
physiologically active in the generation of the lethargy, anorexia and fever induced by 
subcutaneous administration of LPS in rats.  To discern direct effects in the brain of IL-6 
and IL-1β in mediating sickness behaviours, I injected species-homologous rat IL-6 and 
IL-1β directly into the brains of conscious rats and examined the dose-response effects on 
their voluntary activity, food intake and body temperature in Chapter 3.  Chapter 3 also 
looks at whether IL-6 and IL-1β act synergistically within the brain to mediate changes in 
voluntary activity, food intake and body temperature.  In Chapter 4 I investigate the 
effects of inhibiting the action of peripherally-released IL-6 and IL-1β in the brain on 
lethargy, anorexia and fever induced by subcutaneous administration of LPS.  In Chapter 
5, the experimental results presented in the thesis are summarized, unresolved issues are 
discussed, and conclusions and recommendations are given. 
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CHAPTER 1 
 
INTRODUCTION 
 
 2 
Pathogenic microorganisms which succeed in overcoming the physical barriers to access 
the human body trigger a set of immune, physiological, metabolic and behavioural 
responses in the host, known collectively as the acute phase response (Dantzer, 2004).  Of 
these acute phase responses, fever is the most commonly recognized and it is identified 
by physicians and patients alike as an elevation of body temperature.  Not only will most, 
if not all patients have high body temperatures during infectious and inflammatory 
illness, but so too will they experience a cluster of non-specific behavioural changes such 
as lethargy, depression, increased sleepiness and pain, and suppression of appetite (Hart, 
1988; Dantzer, 2001; Johnson, 2002).  These behavioural changes, collectively referred to 
as “sickness behaviour” are now well-established responses to infection and together with 
fever constitute a highly organized and evolved strategy used by the host to fight 
infection (Hart, 1988).    
 
Part of the innate immune system’s response to infection includes the production of pro-
inflammatory cytokines, the involvement of which in the pathogenesis of fever was 
identified in the late 1970’s (Dinarello et al., 1977; Dinarello, 1999).  The pro-
inflammatory cytokines thought to have significant roles in fever include tumour necrosis 
factor (TNF), interleukin-1 (IL-1) and interleukin-6 (IL-6), synthesized by 
monocytes/macrophages and lymphocytes (Luheshi & Rothwell, 1996).  Approximately 
ten years after a role for cytokines in fever was uncovered, evidence began to emerge that 
cytokines also may be involved in the induction of the sickness behaviours accompanying 
fever.  The evidence came from clinical trials in which purified or recombinant cytokines 
were used in the treatment of patients with cancer and chronic viral infections such as 
 3 
hepatitis B and C.  Administering cytokines to these patients produced a number of side-
effects which included lethargy, weakness, malaise, sleep changes as well as fever 
(Renault & Hoofnagle, 1989; Dinarello, 1997).  It quickly became apparent to clinicians 
and researchers that these effects observed with systemic administration of cytokines 
were akin to those experienced by sick animals and humans.  Since these observations 
obtained from clinical studies, experimental administration of pro-inflammatory 
cytokines to animals has confirmed that most components of sickness behaviour can 
indeed be induced by pro-inflammatory cytokines, in particular IL-1 (for review see 
Dantzer et al., 1998; Dantzer, 2004). 
 
Although exogenous administration of cytokines in animals and humans induced sickness 
behaviour, there nevertheless remained doubt as to whether cytokines synthesized 
endogenously during infection mediated sickness behaviour.  It was proposed that the 
injection of recombinant cytokines may be at pharmacological doses, inducing effects 
which are not necessarily representative of the true physiological effects occurring in an 
infected individual.  Moreover, during an actual or simulated infection not only one, but a 
number of different cytokines are synthesized and these cytokines can affect the synthesis 
and secretion of each other (Cartmell & Mitchell, 2005).  Thus it became clear that an 
understanding of the cytokine mechanisms mediating fever and sickness behaviour 
during an infection would need investigations into the contribution of each individual 
cytokine in mediating sickness responses.   
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The development of techniques which allowed specific antagonism of individual 
cytokines, such as receptor antagonists, neutralizing antibodies against cytokines and 
their receptor molecules, and gene knockout technology, assisted researchers in 
undertaking investigations into the respective roles of cytokines.  These techniques were 
combined with an established animal model of simulated infection induced by a powerful 
activator of the innate immune system, lipopolysaccharide (LPS), the glycolipid 
pyrogenic moiety of the Gram-negative bacterial membrane, injected into various animal 
species via various routes (Ulevitch & Tobias, 1995).  
 
This introductory chapter summarizes the current views on how the response of the innate 
immune system to administration of LPS leads to the synthesis of pro-inflammatory 
cytokines, and it reviews the literature on pro-inflammatory cytokines as mediators of 
fever and sickness behaviours, specifically anorexia and lethargy, induced by LPS.  The 
questions to be addressed in this thesis also are raised. 
 
1.1 Bacterial-host interactions 
 
A substantial portion of our knowledge on host defence responses and inflammatory 
mediators during an infectious episode has been derived from studies investigating host 
responses to LPS administration (Heumann & Roger, 2002).  The interest in this 
molecule and the mechanism of its biological action have significant clinical application, 
as Gram-negative sepsis in humans is caused by Enterobacteriaceae such as Escherichia 
coli and Klebsiella species (Bochud & Calandra, 2003).  LPS is composed of two 
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chemically dissimilar structural regions:  the hydrophilic repeating polysaccharides of the 
core and the O-antigen structures, and a hydrophobic domain known as lipid A.  Lipid A 
is the biologically active moiety of LPS (Heumann & Roger, 2002).  Of the different 
components (LPS, peptidoglycan, porins, pipoproteins, lipopeptides, lipid A-associated 
proteins, pili, flagellin, DNA (CpG motifs) and endotoxins) of Gram-negative bacteria 
known to induce inflammation, LPS is proposed to be the most potent (Heumann & 
Roger, 2002). 
 
1.1.1 Detection of Gram-negative bacteria through cellular receptors 
 
Once bacterial components have entered the host, the innate immune system recognizes 
the presence of a given pathogen by the so-called pathogen-associated molecular patterns 
(PAMPs) present on microbes, but not expressed by the host (Janeway & Medzhitov, 
2002; Kapetanovic & Cavaillon, 2007).  PAMPs are specific, structurally conserved 
components of certain broad groups of microorganisms (Romanovsky et al., 2006).  
Classical bacterial PAMPs include LPS of Gram-negative bacteria and lipoteichoic acid 
or peptidoglycans from Gram-positive bacteria.  Detection of PAMPs present on 
microbes is mediated by pattern recognition receptors expressed on the surface of innate 
immune cells of the host (Kapetanovic & Cavaillon, 2007).  The pattern recognition 
receptors for PAMPs are germ line encoded receptors known as Toll-like receptors 
(TLR), which are transmembrane proteins that relay PAMPs-induced signals across the 
cell-surface membrane (Kapetanovic & Cavaillon, 2007). 
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There is substantial evidence to indicate that LPS acts via the TLR-4 receptor subtype of 
the TLR family (Chow et al., 1999).  However, for LPS in plasma to confirm 
responsiveness via its TLR, its lipid A domain has to bind at least two non-signalling host 
accessory proteins: the constitutive serum protein LPS-binding protein (LBP), and 
soluble or membrane-bound CD14 (see below) (Cartmell & Mitchell, 2005).  LBP 
dissociates LPS aggregates to form LPS/LBP complexes which are transferred to CD14.  
The primary role of LBP is therefore to function as a lipid-transfer protein, increasing the 
rate at which LPS interacts with soluble or membrane bound CD14 (Pugin et al., 1993).  
CD14 exists as a protein anchored in the outer leaflet of the plasma membrane (mCD14) 
present on monocytic cells (CD14-positive cells).  It also exists in the form of a soluble 
plasma protein (sCD14) that attaches LPS to CD14-negative cells, such as endothelial 
cells present in blood and fluids (Heumann & Roger, 2002).  CD14 cannot induce 
activation without a transmembrane signal transducing co-receptor, identified as TLR-4 
for LPS (Kapetanovic & Cavaillon, 2007).  The membrane-bound CD14 which binds 
LPS, conveys it to MD-2, a key protein needed for the TLR-4 dependent intracellular 
signalling (Kapetanovic & Cavaillon, 2007).  As Figure 1 illustrates LPS therefore 
initiates its effects through a heteromeric receptor complex containing CD14, together 
with the transmembrane protein TLR-4 (Medzhitov & Janeway, 1997), and at least one 
other protein, MD-2, which is essential to confer LPS responsiveness via its TLR 
(Shimazu et al., 1999).   The importance of TLR-4 in mediating the immune response to 
LPS has been confirmed in vivo with the finding that TLR-4-deficient mice do not 
respond to LPS (Hoshino et al., 1999).  While TLR-4 appears to be the primary 
mechanism mediating LPS recognition, other receptors such as CD11/CD18 beta-2 
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integrin and cell-surface proteins known as scavenger receptors may also be involved 
(Romanovsky et al., 2005). 
 
Once LPS binds to TLR-4 present on the surface of leucocytes, this leads to signal 
transduction via receptor associated proteins, IL-1 receptor-associated kinase, myeloid 
differentiation factor 88 (MyD88) and TNF receptor-associated factor (TRAF6), resulting 
in the activation of transcription factors (nuclear factor-κB and activator protein 1) 
(Cartmell & Mitchell, 2005).  Although TLR-4 signalling can also occur through a 
MyD88 independent pathway, the MyD88 pathway depicted in Figure 1 is essential for 
the inflammatory response mediated by LPS.  The transcription factors control the 
expression of immune response genes, which ultimately leads to the synthesis and release 
of cytokines (Heumann & Roger, 2002; Cartmell & Mitchell, 2005; Kapetanovic & 
Cavaillon, 2007).   
 
The focus of the discussions of this review will be on the involvement of four principal 
cytokines (TNF-α, IL-1β, IL-6 and leptin) as endogenous mediators of fever, anorexia 
and lethargy induced by LPS.   
 
 8 
 
 
Figure 1.  Lipopolysaccharide aggregates are dissociated by LBP to form LPS/LBP 
complexes which are transferred to CD14.  A small cysteine rich secreted glycoprotein, 
MD-2, is essential for TLR-4 signalling, which leads to signal transduction via receptor 
associated proteins, IRAK, MyD88 and TRAF6, resulting in the activation of 
transcription factors (NF-κB and AP-1).  The transcription factors control the expression 
of immune response genes, which ultimately leads to the synthesis and release of 
cytokines.  Abbreviations: Lipopolysaccharide (LPS), LPS-binding protein (LBP), Toll-
like receptor 4 (TLR4), IL-1 receptor-associated kinase (IRAK), myeloid differentiation 
factor 88 (MyD88), TNF receptor-associated factor 6 (TRAF 6), nuclear factor-κB (NF-
κB), and activator protein 1 (AP-1) (modified from Cartmell & Mitchell, 2005). 
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1.1.2 From LPS-induced synthesis to detection of cytokines through cellular receptors 
 
The experimental model of systemic infection, that is intravenous (i.v.) or intraperitoneal 
(i.p.) administration of LPS to laboratory animals, has been by far the most popular 
model used to investigate fever and sickness behaviour responses.  The rationale for 
administering LPS systemically is that it mimics responses induced by bacterial 
septicaemia, in which the exogenous pyrogen is present in the circulation.  Injection of 
LPS into a pre-formed subcutaneous airpouch is used as an experimental model of sterile 
localized infection.  In this experimental model the exogenous pyrogen remains at the site 
of administration, and so does not enter the circulation.  In response to i.v. or i.p. 
administration of LPS, TNF-α appears first in the circulation, followed by trace amounts 
of IL-1β and large amounts of IL-6 (Givalois et al., 1994).  Injection of LPS into a 
preformed subcutaneous airpouch induces a significant elevation in the concentration of 
TNF-α, IL-1β and IL-6 (in that sequence) at the site of infection (that is within the 
pouch), but IL-6 is the only cytokine detected in the circulation (Miller et al., 1997b; 
Cartmell et al., 2000).  Thus the pattern of cytokines induced in the circulation during 
experimental models of systemic and localized infection appears to differ. 
 
Not only have pro-inflammatory cytokines been detected in the circulation following 
systemic administration of LPS, but they also appear in the brain (Rivest et al., 2000).    It 
has been suggested that these cytokines in the brain could be derived from the periphery 
or they could be synthesized de novo within the brain following the systemic immune 
challenge.  Potential sources of cytokine synthesis in the brain include microglia, 
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astrocytes, neurones and endothelial cells (Rothwell et al., 1996).   Whether in the 
periphery or the brain, cytokines produce their selective biological effects by binding to 
specific membrane-bound receptors, thereby triggering a cascade of events, leading to 
signal transduction which promotes transcription and upregulation of expression of 
specific target genes, for example those for the synthesis of cyclooxygenase (COX) (a 
detailed description of the signal-transduction pathways for IL-1, TNF and IL-6, is 
provided in the review by Cartmell & Mitchell, 2005).   
 
The IL-1 cytokine family consists of two agonists, IL-1α and IL-1β, and a highly 
selective endogenous IL-1 receptor antagonist (IL-1ra) (Dinarello, 1991).  In vivo all 
three cytokines are synthesized initially as precursors, of which pro-IL-1α and pro-IL-1ra 
are biologically active.  Pro-IL-1β is inactive as it lacks a signalling peptide, and 
therefore remains inside the cell in which it was synthesized (Thornberry et al., 1992; 
Burns et al., 2003).  To be biologically active, pro-IL-1β requires proteolytic cleavage by 
an enzyme known as caspase-1 or interleukin-1-converting-enzyme to active mature IL-
1β, which is then secreted from the cell (Thornberry et al., 1992; Fantuzzi & Dinarello, 
1999; Burns et al., 2003).    There are no differences between the biological actions of IL-
1β and IL-1α (Dinarello, 2005b).   However, IL-1α is thought to remain mainly cell-
associated, while IL-1β is secreted and therefore, more likely to play a role in the 
physiological responses such as fever and sickness behaviour (Dinarello, 2005b).  IL-1α, 
IL-1β and IL-1ra all bind the same IL-1 receptors on target cells: type I (IL-1rI) and type 
II (IL-1rII) IL-1 receptors (Dinarello, 1991; Conti et al., 2004).  IL-1 exerts its biological 
effects through initial interaction with the IL-1rI receptor to form a functional signalling 
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receptor complex (Sims et al., 1993; Lang et al., 1998).  The IL-1rII receptor acts as a 
“decoy” molecule binding IL-1 with high affinity yet it fails to activate the signalling 
cascade (Lang et al., 1998). 
 
Like IL-1, TNF occurs in two forms, α and β (Cartmell & Mitchell, 2005).  Of the two 
different forms, TNF-α is proposed to be primarily involved in the physiological 
responses of fever and sickness behaviour.  There are two transmembrane signalling 
receptors, type I (TNFRI, p55) and type II (TNFRII, p75), by which TNF mediates its 
pleiotropic effects (Bazzoni & Beutler, 1996).  A third soluble receptor also exists that 
acts endogenously as an antagonist of TNF activity (Himmler et al., 1990).   
 
The biological effects of IL-6 are mediated by a specific receptor complex that consists of 
two functionally different subunits: a specific ligand-binding receptor (IL-6R), not 
capable of transducing activity; and a non-ligand binding signal transducing glycoprotein 
(gp 130) (Cartmell & Mitchell, 2005).   Together IL-6R and gp 130 form a high-affinity 
IL-6 binding site that triggers specific transduction signals (Kishimoto et al., 1995).  
Soluble forms of the ligand-binding IL-6 receptor subunit have also been discovered 
(Rivest et al., 2000; Roth et al., 2004b).  These soluble IL-6 receptors can bind IL-6 and 
associate with cellular gp130 to initiate signal transduction (Roth et al., 2004b). 
 
Leptin is a 16kDA pleitrophic protein encoded by the ob gene, which belongs to the long-
chain helical cytokine family that also includes IL-6 and is produced mainly by white 
adipose cells (Zhang et al., 1994).  The biological effects of leptin are induced by 
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signalling via the long isoform of the leptin receptor, ObRb (Bates et al., 2003; Bates et 
al., 2004).  The ObRb receptor has signalling activities similar to those of the IL-6 type 
cytokine receptors (Vaisse et al., 1996). 
 
Receptors for IL-1, IL-6, TNF and leptin have been identified on peripheral cells and they 
have been localized in the brain of rodents (Hopkins & Rothwell, 1995; Zabeau et al., 
2003).  Having discussed the interactions between LPS and immune cells, which lead to 
the synthesis of pro-inflammatory cytokines in response to systemic administration of 
LPS, the subsequent sections summarize the findings obtained from studies using genetic 
ablation or physiological antagonism of a particular cytokine or its receptor to investigate 
the action of specific cytokines, released in the periphery and the brain, in mediating the 
sickness responses of fever, anorexia and lethargy induced by peripheral administration 
of LPS.  These findings also are compared with those obtained from the more commonly 
used pharmacological approaches of cytokine administration. 
 
1.2 Cytokines as mediators of fever induced by LPS 
 
It is generally believed that the febrile response is mostly beneficial to the host acutely, as 
an increase in body temperature has been shown to potentiate specific immunological 
responses and inhibit the growth of at least some viral and bacterial pathogens (Hart, 
1988).  The increase of body core temperature that occurs during a fever appears to be 
due to a regulated elevation of the temperature set point resulting from changes in the 
firing rates of neurones localized in the preoptic area of the hypothalamus (Conti et al., 
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2004).  It has been suggested that during fever, pyrogenic molecules decrease firing rates 
of warm-sensitive neurones, and increase firing rates of cold-sensitive neurones (as a 
consequence of synaptic inhibition), thereby suppressing heat-loss responses and 
enhancing heat production and heat-retention responses (Mackowiak & Boulant, 1996).   
These changes in firing rates have been reported in studies using ex vivo protocols, which 
included administration of recombinant TNF-α, IL-1β and IL-6 to hypothalamic tissue 
slices, and are similar to the responses observed in conscious febrile animals (Shibata & 
Blatteis, 1991).  Thus it has been proposed that pro-inflammatory cytokines are the likely 
pyrogenic molecules acting within the hypothalamus to increase the temperature set-point 
during fever, which results in the relative changes in firing rates of thermo-sensitive 
neurones (Hori et al., 1988; Nakashima et al., 1989; Nakashima et al., 1991; Shibata & 
Blatteis, 1991; Xin & Blatteis, 1992).   
 
1.2.1 Interleukin-1β 
 
IL-1β was the first cytokine considered to be an endogenous pyrogen.  The initial 
evidence was based on the findings that peripheral and central injections of recombinant 
IL-1β into various laboratory animals induces fever (Dascombe et al., 1989; Murakami et 
al., 1990; Cao et al., 2001).  Although IL-1β may be a potent pyrogenic cytokine when 
injected systemically (Dascombe et al., 1989), there remains uncertainty concerning its 
involvement as an endogenous pyrogen mediating fever induced by systemic 
administration of LPS.  The uncertainty surrounding IL-1β as an endogenous pyrogen has 
arisen because of the poor correlation noted between the fever response and plasma IL-1β 
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concentrations (Kluger, 1991), the repeated failure of many studies to detect biologically 
active IL-1β in plasma during simulated infections (Hopkins & Humphreys, 1989, 1990) 
and the contradictory findings obtained from studies in which IL-1β antagonism was used 
to investigate the involvement of IL-1β in LPS-induced fevers.  In support of IL-1β 
acting as an endogenous pyrogen, are the reports that fever in response to peripheral LPS 
administration is inhibited by: (i) peripherally administered IL-1β antiserum or IL-1ra 
(Long et al., 1990b; Smith & Kluger, 1992; Luheshi et al., 1996; Miller et al., 1997a) and 
(ii) centrally administered IL-1β antiserum or IL-1ra (Klir et al., 1994; Luheshi et al., 
1996; Miller et al., 1997a; Cartmell et al., 1999).  Reports not in favour of IL-1β acting as 
an endogenous pyrogen are the findings that IL-1β knockout mice, mice which are 
deficient in IL-1β production, respond with only a slightly reduced (Kozak et al., 1995b) 
or even enhanced (Alheim et al., 1997) fever following LPS administration, and mice 
deficient in the IL-1 type I receptor respond with virtually the same fevers as wild-type 
mice (Leon et al., 1996; Labow et al., 1997).  Therefore, IL-1β appears to play a role, 
though perhaps not an essential role in fever induced by systemic and local administration 
of LPS. 
 
1.2.2 Interleukin-6 
 
In contrast to the minor role proposed for IL-1β in mediating LPS-induced fever, the role 
of IL-6 appears to be a major one.  The first pieces of evidence in support of IL-6 as an 
endogenous pyrogen in both humans and experimental animals came from the 
observations of excellent correlations between the magnitude and duration of the fever 
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response and plasma IL-6 concentrations (Nijsten et al., 1987; LeMay et al., 1990).  
Moreover, injecting recombinant IL-6 into the brains of rats (LeMay et al., 1990; 
Dinarello et al., 1991) and systemically in rabbits (Helle et al., 1988) induced fever.  
Since these early findings, a critical role for endogenous IL-6 in LPS-induced fever has 
been confirmed by the finding that IL-6 knockout mice, mice carrying a null mutation in 
the IL-6 gene and therefore defective IL-6 production, do not develop a fever when 
injected with a low dose of LPS (50 µg kg-1) (Chai et al., 1996; Kozak et al., 1998).  
Having established that IL-6 is indeed a critical endogenous pyrogen, the question arose 
as to whether the fever response induced by systemic and local administration of LPS 
required the central (brain-based) or peripheral pool of IL-6.  The finding that central and 
not peripheral administration of IL-6 induced fever in wild-type mice, lead to the 
speculation that it is the action of IL-6 within the brain which is important for fever.   
However, more recently the studies of Cartmell et al., (2000) and Rummel et al., (2006) 
have shown that neutralizing the action of IL-6 in the periphery using a species-specific 
IL-6 antiserum, completely prevented fever from occurring following localized 
administration of LPS.  Thus there is direct evidence that not only centrally released, but 
also peripherally-released IL-6 can act as an essential signal to the brain to induce fever.  
 
1.2.3 Tumour-necrosis factor 
 
The body temperature effects of IL-1β and IL-6 always are those of an increase in body 
temperature.  TNF-α on the other hand, has been reported to have both body temperature 
raising (pyrogenic) and body temperature lowering (antipyretic) actions.   In favour of a 
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pyrogenic action for peripherally-released TNF-α are reports that LPS-induced fever is 
attenuated in: (i) rabbits treated with monoclonal TNF-α antibodies (Kawasaki et al., 
1989), (ii) rolipram, a type-IV phosphodiesterase inhibitor that inhibits the production of 
TNF-α (Mabika & Laburn, 1999) and (iii) guinea-pigs treated with a TNF-binding 
protein known to be a potent inhibitor of TNF-α (Roth et al., 1998).   In contrast an 
antipyretic action of peripherally-released TNF-α is supported by reports that: (i) 
neutralizing the peripheral action of endogenously produced TNF-α using antiserum 
against TNF or soluble TNF receptors, enhanced the fever induced by LPS administration 
in rats (Long et al., 1990a; Klir et al., 1995), (ii) systemic administration of a low dose of 
TNF-α (which on its own has no effect on body temperature) attenuated LPS-induced 
fever in rats (Long et al., 1992; Klir et al., 1995; Kozak et al., 1995a) and (iii) mice 
lacking both the TNF p55 and p75 receptors developed larger fevers in response to LPS 
administration, than did wild-type mice (Leon et al., 1997). 
 
It has been proposed that the pyrogenic or antipyretic effects of TNF-α may depend on 
the species of experimental animal used, as closer examination of the results presented 
above show that TNF-α appears to be a pyrogenic molecule in rabbits and guinea-pigs, 
but not in rats and mice.  Moreover, the different actions of TNF-α in the fever pathway 
also may be related to the dose of the fever-inducing agent used, as injection of a low 
dose (50 µg kg-1 i.p.) of LPS produced similar fever responses between TNF p55/p75 
knockout mice and wild-type mice, while injection of a higher dose of LPS (2.5 mg kg-1 
i.p.) resulted in larger fevers in TNF p55/p75 knockout mice (Leon et al., 1997).  
Injecting rats with high, septic-like doses of LPS (2.5 mg kg-1) produces significantly 
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greater concentrations of TNF-α in serum compared to that measured when injecting 
lower doses of LPS (Long et al., 1990a; Sharma et al., 1992).  It is possible therefore, that 
feedback mechanisms exist which are activated by the concentration of the cytokine 
itself, whereby moderate increases in circulating TNF-α act to increase body temperature, 
while greater concentrations of circulating TNF-α act as a signal to reduce body 
temperature (Kluger et al., 1995; Conti et al., 2004).   
 
1.2.4 Leptin 
 
Following reports that circulating concentrations of leptin increase acutely with LPS 
administration (Sarraf et al., 1997; Faggioni et al., 1998; Finck et al., 1998) and in a 
similar fashion to known pyrogenic cytokines such as IL-6, a number of investigations 
examining the role of leptin in the fever pathway were undertaken.  Initial evidence in 
support for leptin as an endogenous pyrogen was based on the findings that the febrile 
response to systemic administration of LPS was largely attenuated in Zucker fa/fa rats, 
rats in which the receptor-mediated transport and intracellular signalling of leptin are 
defective (Rosenthal et al., 1996). Moreover, peripheral and central injection of 
recombinant leptin into rats induced fever (Luheshi et al., 1999).   
 
Studies undertaken subsequently have revealed that these early findings supporting the 
involvement of leptin in the fever pathway may however, be more complicated to 
interpret than was initially thought, as the febrile response of Zucker fa/fa rats varied 
depending on the ambient temperature at which the studies were conducted (Ivanov & 
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Romanovsky, 2002; Steiner et al., 2004).  Injecting these mutant rats systemically with a 
low dose of LPS resulted in a polyphasic fever in a thermally neutral environment, but an 
attenuated fever in a cool environment (Ivanov & Romanovsky, 2002; Steiner et al., 
2004).  It is known that in a cold environment rats depend on brown fat thermogenesis 
not only to regulate body temperature normally but also to produce a febrile response 
(Ivanov & Romanovsky, 2002).  Zucker fa/fa rats are not capable of activating brown fat 
thermogenesis however, as their brown fat is morphologically and functionally defective 
(Seydoux et al., 1990).  The attenuated fever response observed in Zucker fa/fa rats 
housed in a cool environment, may therefore be due to a lack of thermogenesis, rather 
than the absence of leptin signalling per se.  That these mutant rats responded with a 
polyphasic fever similar to that noted in non-mutant rats in a thermally neutral 
environment, suggested that leptin signalling is not required in the febrile response.  
These negative findings should be viewed with caution however; studies have shown that 
the fatty mutation in Zucker rats may in fact permit normal functioning of the leptin 
receptor in at least some experimental paradigms (Wang et al., 1998; Ivanov & 
Romanovsky, 2002).   
 
More substantial evidence in support of leptin as an endogenous pyrogen has emerged 
with the use of antibodies to antagonize circulating leptin following peripheral 
administration of LPS; LPS-induced fever was significantly attenuated (Sachot et al., 
2004).  Under some experimental conditions peripherally-released leptin therefore does 
appear to contribute to mediating the fever response induced by systemic administration 
of LPS. 
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1.2.5 The relative contributions of cytokines released in the periphery and the brain in                                                  
         mediating LPS-induced fever 
 
Table 1 summarizes the research findings discussed in the sections above where the roles 
of cytokines released in the periphery and the brain in mediating fever induced by 
systemic and local administration of various doses of LPS were investigated using 
techniques which allowed selective inhibition or blockade of cytokine actions or effects.  
To account for the involvement of cytokines in mediating fever being dependent on the 
magnitude of the fever response, the studies included in Table 1 administered LPS over a 
broad range of doses (10 µg kg−1 - 2500 µg kg−1).  In these studies the relative 
contribution of a particular cytokine is rated by whether the fever response is abolished, 
attenuated or not affected (-) when the cytokine effect is absent.  Clearly the findings of 
no effect, attenuation or abolition obtained from studies using techniques which allowed 
selective inhibition or blockade of cytokine actions or effects need to be interpreted in 
light of the fact that the results may depend on whether the dose of the antagonist used 
completely neutralized the action of a given cytokine within the specific compartment 
(peripheral or central) into which it is injected.  Of the findings presented in Table 1 the 
most prominent are the complete abolition of the fever response when the effect of IL-6 is 
absent.  The creditability of these findings are strengthened by the observations that: (i) 
the use of two different techniques to block the action of IL-6, genetic ablation and 
immunological antagonism, yielded similar finding, and (ii) the study of Cartmell et al., 
(2000) reported undetectable concentrations of IL-6 in the plasma of rats that received 
LPS and the IL-6 antiserum.   
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Table 1. The effect of antagonizing the action of cytokines released in the periphery and the brain on fever induced by LPS 
 
 Fever LPS dose and route Animal species References 
Interleukin-6     
Peripheral administration of:      
IL-6 antibodies Abolished 100 µg kg-1, i.po. Rats Cartmell et al., 2000  
Rummel et al., 2006 
     
Central administration of:     
IL-6 antibodies Attenuated 1000 µg kg-1, i.p. Rats Rothwell et al., 1991 
     
IL-6 knockout mice Abolished 50 µg kg-1, i.p. Mice Chai et al., 1996 
IL-6 knockout mice ▬ 2500 µg kg-1, i.p. Mice Kozak et al., 1998 
     
Interleukin-1β     
Peripheral administration of:     
IL-1ra Attenuated 100 µg kg-1, i.p. Rats Luheshi et al., 1996 
IL-1β antibodies Attenuated 10 µg kg-1, i.p. Rats Long et al., 1990b 
     
Central administration of:     
IL-1ra Attenuated 100 µg kg-1, i.p. Rats Luheshi et al., 1996 
IL-1ra Attenuated 100 µg kg-1, i.po. Rats Cartmell et al., 1999 
IL-1β antibodies Attenuated 50 µg kg-1, i.p. Rats Klir et al., 1994 
     
IL-1β knockout mice Attenuated 2500 µg kg-1, i.p. Mice Kozak et al., 1995b 
IL-1 type I knockout mice ▬ 50 µg kg-1, i.p. Mice Leon et al., 1996 
IL-1 type I knockout mice ▬ 2500 µg kg-1, i.p. Mice Leon et al., 1996 
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Table 1. continued 
 
 Fever LPS dose and route Animal species References 
Tumour necrosis factor-α     
Peripheral administration of:     
TNF-α antibodies Attenuated 0.625 µg kg-1, i.v. Rabbits Kawasaki et al., 1989 
TNF-binding protein Attenuated 10 µg kg-1, i.a. Guinea pigs Roth et al., 1998 
TNF-receptor antagonist ▬ 20 µg kg-1, i.m. Guinea pigs Roth et al., 1997 
TNF-α antibodies Enhanced 10 µg kg-1, i.p. Rats Long et al., 1990a 
TNF soluble receptors Enhanced 50 µg kg-1, i.p. Rats Klir et al., 1995 
 
    
TNF double-receptor knockout mice ▬ 50 µg kg-1, i.p. Mice Leon et al., 1997 
 
    
Leptin     
Peripheral administration of:     
Leptin antibodies Attenuated 100 µg kg-1, i.p. Rats Sachot et al., 2004 
     
Leptin receptor-deficient rats  
(Koletsky rats) 
▬ 10 µg kg-1, i.v. Rats Steiner et al., 2004 
Leptin receptor-deficient rats  
(Koletsky rats) 
▬ 100 µg kg-1, i.v. Rats Steiner et al., 2004 
Zucker (fa/fa) rats ▬ 10 µg kg-1, i.v. Rats Ivanov & Romanovsky, 2002 
 
i.po. = intrapouch, i.p. = intraperitoneal, i.v. = intravenous, i.a. = intra-arterial, i.m. = intramuscular 
▬ = no effect 
Studies of the present thesis are excluded from this table 
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The attenuated responses noted when the effect of IL-1β was absent appeared also to 
accurately reflect the contribution of IL-1β in mediating LPS-induced fever, as most of 
the studies reported that increasing the dose of the cytokine antagonizing agent did not 
produce a greater attenuation of the LPS-induced fever (Luheshi et al., 1996; Cartmell et 
al., 1999).  The role of TNF-α in mediating LPS-induced fever appears more complex 
and less clear than that of IL-6 and IL-1β, as findings obtained from studies in which 
complete neutralization of TNF-α was confirmed, found attenuated (Roth et al., 1998) or 
enhanced (Long et al., 1990a) fevers.  Not only is there uncertainty concerning the role of 
TNF-α in mediating LPS-induced fever but so too for leptin.  While peripheral 
administration of leptin antibodies attenuated LPS-induced fever no effect was noted in 
leptin receptor-deficient rats (Steiner et al., 2004) and Zucker rats (Ivanov & 
Romanovsky, 2002).   
 
From the findings presented in Table 1 it therefore appears that while other cytokines 
released in the periphery and the brain may play contributory roles, endogenous 
circulating IL-6 is likely to be the major endogenous pyrogen mediating fever in response 
to systemic and localized infection induced by LPS (50 and 100 µg kg-1).   Irrespective of 
the relative roles played by the various endogenous cytokines in fever, the question arises 
as to whether cytokines are the final mediators of fever and if not which other molecules 
are the most likely candidates for this function.   
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1.2.6 Brain mediators of cytokine effects on body temperature  
 
Exposure of the host to an exogenous pyrogen such as LPS not only results in the release 
of pro-inflammatory cytokines, but also results in the release of a number of enzymes that 
catalyse the formation of small signalling molecules such as prostaglandin E2 (PGE2).  
The formation of PGE2 depends on the activity of the cyclooxygenase (COX) enzyme, 
which exists in two isoforms, the constitutively expressed COX-1 and the inducible form 
COX-2 (Ivanov & Romanovsky, 2004).  The synthesis of PGE2 via the induction of 
COX-2 is a key event in the fever response, as it has been shown that mice which lack 
PGE2 synthesizing enzymes do not develop a fever in response to LPS administration (Li 
et al., 1999; Engblom et al., 2003).  It is likely that endogenous cytokines induce fever 
following peripheral administration of LPS via the generation of these PGE2 synthesizing 
enzymes, as neutralization of endogenous circulating IL-6 also attenuates COX-2 
upregulation in the cerebral microvasculature of rats (Rummel et al., 2006) and the 
changes in firing rates of thermoregulatory neurones induced with administration IL-1β 
and IL-6 to tissue slices obtained from guinea pigs and rats, is prevented by concurrent 
administration of COX inhibitors (Hori et al., 1988; Xin & Blatteis, 1992).  
 
1.3 Cytokines as mediators of the anorexia induced by LPS 
 
Loss of appetite and the concomitant decrease in food intake is frequently observed in 
sick humans and animals, and along with fever forms the most common sign of infection 
observed in both the clinical and experimental situation (Plata-Salaman, 1996a).  The 
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anorexia experienced during illness appears to be a robust phenomenon that occurs 
throughout a broad variety of species, as well as in response to various different 
infectious agents.  It is a valuable short-term response aimed at supporting the 
immunological response of the host to eliminate the pathogen (Murray & Murray, 1979; 
Hart, 1988; Exton, 1997) and it does not appear to be a consequence of fever, as it can 
occur in the absence of fever (McCarthy et al., 1985; O'Reilly et al., 1988).   
 
It is generally believed that illness-related anorexia results from the modulation of normal 
homeostatic processes that regulate feeding in healthy individuals (Langhans, 2007).  As 
such it has been proposed that the loss of appetite observed during infection must 
eventually result from signalling to a final pathway for appetite control that resides within 
the brain (Plata-Salaman, 1998a).  Injection of cytokines into the hypothalamus and 
cerebral ventricles of rats has been shown to inhibit feeding (Kent et al., 1994; Sonti et 
al., 1996).  It is likely therefore that cytokines could act as these signalling molecules 
within the brain to reduce food intake during infection.  A common and related effect of 
infection and cytokine administration is a decrease in body mass (Bluthé et al., 1992b; 
Bluthé et al., 1994a; Leon et al., 1996), which at least acutely, is thought to reflect the 
decreased food intake.  
 
1.3.1 Interleukin-1β 
 
Reports from numerous studies have compellingly demonstrated that IL-1β 
administration is particularly potent at reducing appetite in humans and experimental 
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animals (Plata-Salaman & Ffrench-Mullen, 1992; Langhans et al., 1993; Plata-Salaman, 
1996b; Sonti et al., 1996; Montkowski et al., 1997; Pecchi et al., 2006).  The loss of 
appetite is observed when IL-1β is injected into the periphery or the brain of experimental 
animals, indicating that IL-1β can act from both sites to induce anorexia (Kent et al., 
1996).  The anorexigenic responses induced with the administration of IL-1β are similar 
to those seen following LPS administration (Plata-Salaman et al., 1988).  Subsequent 
studies have shown however, that the anorexigenic responses observed with 
administration of IL-1β do not appear to reflect the pathophysiological mechanism by 
which systemic administration of LPS induces anorexia.  Administration of IL-1ra 
peripherally or centrally, failed to attenuate anorexia induced by systemic administration 
of LPS in rats (Kent et al., 1992b).  Moreover, mice genetically deficient in IL-1β or the 
IL-1 type I receptor demonstrated similar reductions in food intake and body mass 
following systemic administration of LPS as those of wild-type mice (Kozak et al., 
1995b; Leon et al., 1996).  Although IL-1β may be able to induce anorexia when 
injected, it appears to be of little importance in terms of mediating the decrease in food 
intake observed with systemic administration of LPS. 
 
There have been a few notable exceptions though, in which studies have identified some 
involvement of either peripherally-released or centrally released IL-1β in mediating the 
depressing effects of LPS on food intake and body mass.  Central administration of IL-
1ra attenuated the reduction in food intake induced by systemic administration of LPS in 
mice (Layé et al., 2000), peripheral administration of IL-1ra attenuated the reduction in 
body mass induced by systemic administration of LPS in rats (Bluthé et al., 1992b) and 
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the appetite suppressive effects of centrally, but not systemically, administered LPS were 
attenuated in IL-1β-converting enzyme-deficient mice, mice which do not produce active 
IL-1β (Burgess et al., 1998).  
 
Taken together, these findings are therefore not compatible with an exclusive role of 
endogenous IL-1β in mediating the effects of bacterial products on food intake and body 
mass.  The most likely explanation for the negative findings showing no or little 
involvement of IL-1β in mediating LPS-induced anorexia in the gene knockout mice 
studies (deficient IL-1β, IL-1 type I and IL-1β-converting enzyme) and the IL-1ra studies, 
is that one or several other pro-inflammatory cytokines compensate for the absence of IL-
1β.  An obvious candidate cytokine to compensate for the lack of IL-1β is TNF-α, as 
synergistic effects between IL-1β and TNF-α have been noted in inducing anorexia and 
decreasing body mass in rats and mice (Bluthé et al., 1994a; Sonti et al., 1996). 
 
1.3.2 Tumour-necrosis factor 
 
Although it has been shown that TNF-α can act directly within the brain to suppress food 
intake and decrease body mass in rats (Bluthé et al., 1994a; Sonti et al., 1996; Palin et al., 
2007), as with IL-1β, the evidence in support of an exclusive role for TNF-α in mediating 
anorexia induced by LPS is not convincing and moreover also contradictory.  TNF 
double-receptor knockout mice responded with a similar reduction in food intake and 
body mass as wild-type mice to systemic administration of LPS (Leon et al., 1997), 
whereas rats treated with specific TNF-α antagonists responded with attenuated anorectic 
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responses to systemic administration of LPS (Sharma et al., 1992; Porter et al., 2000; 
Töllner et al., 2000).   
 
Closer examination of the results from these studies reporting an attenuated anorectic 
response revealed two important points, which provide some insight into understanding 
the role of TNF-α in LPS-induced anorexia.  Firstly, it appears that the degree of 
attenuation depends on the dose of LPS administered, as treating rats with the nonspecific 
phosphodiesterase inhibitor pentoxifylline, which inhibits the production of TNF-α in 
vivo (Porter et al., 2000), completely abolished the anorectic effect of i.p. injected LPS 
(100 µg kg-1), but only attenuated the anorectic effect induced by a higher dose of i.p. 
injected LPS (250 µg kg-1) (Porter et al., 2000).  Secondly, following treatment with a 
TNF-binding protein, the attenuation of the anorexia and body mass loss was 
predominantly noted during days two and three after the LPS injection (Töllner et al., 
2000).  Similar findings of a gradual attenuation of the decrease in food intake and body 
mass have also been reported in rats pre-treated with TNF-α monoclonal antibodies 
(Sharma et al., 1992).  The attenuated responses noted in these two studies occurred 
however, during a period when TNF-α would not have been detectable in plasma (Kozak 
et al., 1997b).  Moreover, neutralizing the biological activity of TNF-α did not facilitate 
complete recovery of LPS-induced anorexia, as the food intake and body mass of rats 
injected with LPS and the TNF- binding protein never reached the values of the control 
rats injected with saline.  It is likely that peripherally-released TNF-α is therefore exerting 
its effect by inducing secondary endogenous mediators, which then participate in this 
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anorectic response.  One likely mediator is leptin, a hormone known to regulate feeding 
behaviour (Friedman & Halaas, 1998).   
 
1.3.3 Leptin 
 
Leptin, the product of the ob gene has been shown to be an important central nervous 
system signalling factor for the control of energy balance and body adiposity (Friedman 
& Halaas, 1998).  The concentration of leptin in the circulation primarily indicates the 
production of leptin by white adipocytes, and reflects both long-term (days) and short-
term (hours) changes in leptin production (Steiner & Romanovsky, 2007).  Changes in fat 
storage regulate long-term changes in leptin production and influences the quantity of 
food consumed relative to the amount of energy expended (Friedman & Halaas, 1998).  
The role of leptin and its receptors in the homeostasis of body mass is demonstrated by 
the observations that rodents that have mutations in either their signalling receptors (i.e. 
db/db mice or fa/fa Zucker rats) or in leptin production (i.e. ob/ob mice) are extremely 
obese (Campfield et al., 1995; Halaas et al., 1995).  Short-term changes in the 
concentration of leptin in the circulation can occur independently of body fat mass or loss 
(Steiner & Romanovsky, 2007).  Leptin production is decreased a few hours after the 
onset of fasting, and during conditions of negative energy balance acts as an anti-
starvation signal to suppress energy expenditure and stimulate appetite (Steiner & 
Romanovsky, 2007). 
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The observation that daily i.p. administration of leptin decreases food intake and body 
mass in both obese and non-obese mice (Halaas et al., 1995; Pelleymounter et al., 1995), 
together with the finding that LPS and pro-inflammatory cytokines increase the 
production of leptin in adipose tissue, prompted investigations into the possible role of 
leptin in mediating the appetite-and body mass-reducing effects of LPS (Grunfeld et al., 
1996; Faggioni et al., 1997; Finck et al., 1998).  These studies showed that the increase in 
leptin in the circulation and leptin mRNA in adipose tissue following LPS administration 
correlates with the decrease in food intake (Grunfeld et al., 1996), and leptin receptor-
deficient (db/db) mice are partially resistant to LPS-induced anorexia (Faggioni et al., 
1997).  In support of the findings noted in leptin receptor-deficient mice (db/db) 
suggesting some involvement of leptin in mediating LPS-induced anorexia, others found 
that neutralizing the biological activity of leptin in the circulation significantly attenuated 
the LPS-induced decrease in food intake and body mass in rats (Sachot et al., 2004).  Not 
only did reducing the biological activity of leptin in the circulation prevent LPS-induced 
anorexia, but it also attenuated the up-regulation of IL-1β in the hypothalamus of the rats 
(Sachot et al., 2004).  It is possible then that leptin could be acting in the hypothalamus to 
induce anorexia by increasing IL-1β there (Layé et al., 2000; Sachot et al., 2004).   
 
As noted with the studies investigating the role of leptin in mediating LPS-induced fever, 
the findings for LPS-induced anorexia in animals with genetic defects in the leptin system 
are not always in full agreement with those obtained from studies in which leptin 
antiserum was administered.  Leptin deficient (ob/ob) mice and obese (fa/fa) Zucker rats 
do not exhibit attenuated anorectic responses following LPS administration (Faggioni et 
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al., 1997; Lugarini et al., 2005).  It is unclear why discrepancies have been reported on 
leptin’s role in LPS-induced anorexia.  It has been proposed that humoral mediators, 
other than leptin such as IL-1β and TNF-α (Sachot et al., 2004), may compensate for the 
absence of leptin in animals with genetic defects in the leptin system.  Moreover, due to 
the importance of food intake for survival, the control of food intake is not solely 
dependent on a single pathway, but rather is regulated by different pathways involving 
mediators other than leptin, such as cholecystokinin, insulin and glucagon.  It is possible 
therefore that the absence of the leptin-mediated pathway occurring early on in 
development of mutant animals may merely result in other pathways involved in food 
intake homeostasis compensating.  These alternative pathways could be activated during 
pathological conditions like LPS stimulation, leading to the observed anorexia in db/db 
mice and fa/fa Zucker rats.  In general, while leptin may not be a necessary prerequisite 
or the final mediator of the anorectic response to systemic administration of LPS, it 
nonetheless appears to contribute to the response under some experimental conditions. 
 
1.3.4 Interleukin-6 
 
Of the pro-inflammatory cytokines investigated thus far as mediators of LPS-induced 
anorexia, IL-6 has emerged as the least likely cytokine to be involved.  It can decrease 
food intake in rats when injected peripherally or centrally, but less in comparison to the 
effects noted when other cytokines are administered (Schöbitz et al., 1995; Plata-
Salaman, 1996b; McCarthy, 2000a).  Moreover, IL-6 knockout mice responded with the 
same decrease in food intake as that noted for wild-type mice following systemic 
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administration of LPS (Fattori et al., 1994; Swiergiel & Dunn, 2006).  Interestingly 
though, it appears that peripherally-released IL-6 is involved in mediating the loss of 
body mass induced by systemic administration of LPS in rats (Strassmann et al., 1993; 
Bluthé et al., 2000b).  Whether the involvement of IL-6 in mediating the LPS-induced 
decrease in body mass reported in the studies by Strassman et al., (1993) and Bluthé et 
al., (2000b) was related to changes in food intake is uncertain, as food intake was not 
measured in these two studies.  Body mass loss is a complex variable however, that is 
dependent not only on food intake, but also on excretion of faeces and urine, and 
increased metabolism (Lennie, 1998).  It has been observed that patients infused with IL-
6 exhibit a number of the metabolic changes found in catabolic states (Stouthard et al., 
1995) and rats injected with IL-6 have reduced gastric emptying (McCarthy, 2000b).  IL-
6 may therefore contribute to the cachexia associated with chronic diseases, in which a 
significant part of the severe weight loss is due to the metabolic changes occurring during 
the illness (Strassmann & Kambayashi, 1995; Plata-Salaman, 1996a; Baltgalvis et al., 
2008). 
 
1.3.5 The relative contributions of cytokines released in the periphery and the brain in  
         mediating LPS-induced anorexia 
 
Table 2 summarizes the research findings discussed in the sections above where the roles 
of cytokines released in the periphery and the brain in mediating anorexia induced by 
systemic administration of LPS were investigated using techniques which allowed 
selective inhibition or blockade of cytokine actions or effects.  Studies investigating LPS-
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induced anorexia have assessed feeding responses in rats and mice by measuring either 
the amount of food pellet or sweetened milk consumed (Swiergiel & Dunn, 1999).  
Although milk and food pellet intake are both measures of feeding which are affected 
during infection, milk intake has been shown to be less susceptible to disruption by 
infection than food pellet intake (Swiergiel et al., 1997).  The findings reported in this 
review were therefore restricted to those in which food intake was used as a measure of 
feeding.  The attenuated responses noted when the effect of IL-1β in the brain and TNF-α 
in the periphery were absent appeared to accurately reflect the contribution of these 
cytokines in mediating anorexia induced by systemic administration of LPS, as the 
studies reported that the particular cytokine was not detected in the brain or plasma 
following administration of the respective cytokine or cytokine receptor antagonist 
(Sharma et al., 1992; Layé et al., 2000; Töllner et al., 2000).  The study of Sachot et al., 
(2004) in which leptin antiserum was administered peripherally, did not however provide 
any evidence of the degree of neutralization achieved with the dose of antiserum 
administered.   
 33 
Table 2. The effect of antagonizing the action of cytokines released in the periphery and the brain on anorexia induced by LPS 
 
 Anorexia LPS dose and route Animal species References 
Interleukin-6     
IL-6 knockout mice ▬ 1000 µg kg-1, i.p. Mice Fattori et al., 1994 
IL-6 knockout mice ▬ 1 µg mouse-1, i.p. Mice Swiergiel & Dunn, 2006 
     
Interleukin-1β     
Peripheral administration of:     
IL-1ra ▬ 400 µg kg-1, i.p. Rats Kent et al., 1992b 
     
Central administration of:     
IL-1ra ▬ 400 µg kg-1, i.p. Rats Kent et al., 1992b 
IL-1ra Attenuated 5 µg mouse-1, i.p. Mice Layé et al., 2000 
     
IL-1β knockout mice ▬ 2500 µg kg-1, i.p. Mice Kozak et al., 1995b 
IL-1 type I knockout mice ▬ 2.5 µg mouse-1, i.p. Mice Bluthé et al., 2000a 
IL-1 type I knockout mice ▬ 50 µg kg-1, i.p. Mice Leon et al., 1996 
IL-1 type I knockout mice ▬ 2500 µg kg-1, i.p. Mice Leon et al., 1996 
IL-1β-converting enzyme-deficient mice ▬ 10 µg mouse-1, i.p. Mice Burgess et al., 1998 
 
    
Tumour necrosis factor-α     
Peripheral administration of:     
TNF-α antibodies Attenuated 3000 µg kg-1, i.p. Rats Sharma et al., 1992 
TNF-binding protein Attenuated 5000 µg kg-1, i.p. Rats Töllner et al., 2000 
TNF-binding protein ▬ 1 µg mouse-1, i.p. Mice Swiergiel & Dunn, 1999 
TNF-binding protein + IL-1ra ▬ 1 µg mouse-1, i.p. Mice Swiergiel & Dunn, 1999 
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Table 2. continued 
 
 Anorexia LPS dose and route Animal species References 
Central administration of:     
TNF-binding protein ▬ 1 µg mouse-1, i.p. Mice Bluthé et al., 2000a 
     
TNF double-receptor knockout mice ▬ 50 µg kg-1, i.p. Mice Leon et al., 1997 
TNF double-receptor knockout mice ▬ 2500 µg kg-1, i.p. Mice Leon et al., 1997 
 
    
Leptin     
Peripheral administration of:     
Leptin antibodies Attenuated 100 µg kg-1, i.p. Rats Sachot et al., 2004 
Leptin-receptor deficient mice (db/db) Attenuated 1 µg mouse-1, i.p. Mice Faggioni et al., 1997 
Leptin-deficient mice (ob/ob) ▬ 1 µg mouse-1, i.p. Mice Faggioni et al., 1997 
 
i.p. = intraperitoneal  
▬ = no effect 
Studies of the present thesis are excluded from this table 
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As such it is possible that the degree of attenuation noted in their study may not represent 
the complete contribution of peripherally-released leptin in mediating LPS-induced 
anorexia.  The research findings presented in Table 2 appear to reflect the complexity of 
the interactions between cytokines and/or other molecules in mediating food intake 
during illness, as anorexia induced by systemic administration of LPS is mostly not 
affected by the absence of individual cytokines and when it is affected, the response is 
attenuated only and not abolished.   
 
Whilst important, these studies, unlike those investigating LPS-induced fever, have only 
used an experimental animal model of systemic infection to investigate the role of 
cytokines in mediating LPS-induced anorexia.  Different patterns of cytokines have been 
shown to be induced during systemic and localized infection/inflammation (Fattori et al., 
1994).  Thus the role of cytokines in mediating anorexia may differ depending on the 
origin of the infection.  The involvement of cytokines in mediating anorexia induced 
during a localized Gram-negative bacterial infection has however, not been investigated. 
 
1.3.6 Brain mediators of cytokine effects on feeding  
 
Cytokines can directly (via neuronal mechanisms) or indirectly (via modulation of brain 
chemistry) change the activity of hypothalamic neurones involved in the control of food 
intake (Plata-Salaman & Ffrench-Mullen, 1994; Plata-Salaman, 1996a, 1998b).  The 
neurones are sensitive to changes in the concentration of glucose in the blood (Guyton & 
Hall, 2000).  An increase in the concentration of blood glucose increases the rate of firing 
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of glucose-sensitive neurones in the satiety centre in the ventromedial nuclei (VMN) of 
the hypothalamus (Guyton & Hall, 2000).  The same increase in blood glucose 
concentration simultaneously decreases the firing of glucose-sensitive neurones in the 
hunger centre of the lateral hypothalamic area (LHA) (Guyton & Hall, 2000).  These 
responses predict that inhibition of LHA and activation of VMH will result in anorexia.  
Injecting rats i.c.v. with IL-1-β or TNF-α specifically suppresses the neuronal activity of 
the glucose-sensitive neurons in the LHA (Plata-Salaman et al., 1988), whereas IL-1β 
excites the glucose-sensitive neurones in the VMH (Kuriyama et al., 1990).   
 
The control of feeding also is associated with various neurotransmitter and neuropeptide 
systems in the hypothalamus.  There is substantial data to show that cytokines can 
modulate hypothalamic chemistry by stimulating the synthesis of mediators such as 
prostaglandins, and interacting with various neurotransmitters and neuropeptides within 
the brain.  Although the exact contribution of these direct and indirect actions of cytokine 
mechanisms in mediating the decrease in feeding during infection is yet to be established, 
some of the proposed interactions are discussed below. 
 
1.3.6.1 Prostaglandins 
 
In rats the anorexia induced by systemic administration of LPS is significantly attenuated 
with selective pharmacological or genetic blockade of COX-2-generated prostaglandins 
(Johnson et al., 2002).  The partial, rather than complete, attenuation of food intake has 
lead to the suggestion, that unlike the fever response, prostaglandin-dependent pathways 
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do not seem to be crucially involved in mediating LPS-induced anorexia.  Consistent with 
this observation in laboratory animals, is the clinical observation that patients with 
infections/inflammation receiving antipyretic therapy still exhibit anorexia (Plata-
Salaman, 1996a).  In contrast, selective pharmacological or genetic blockade of COX-2 
generated prostaglandins are very effective antagonists of anorexia induced by 
administration of IL-1β and TNF-α (Bluthé et al., 1992a; Langhans et al., 1993; 
McCarthy, 2000a; Pecchi et al., 2006; Elander et al., 2007).  The differential importance 
of prostaglandins in mediating LPS versus cytokine induced anorexia, not only identifies 
distinct mechanisms of action, but also is consistent with the view that endogenous IL-1β 
and TNF-α are not exclusive mediators of the anorectic effects of LPS (Langhans, 1996). 
 
1.3.6.2 Neuropeptides 
 
The interaction between cytokines and neuropeptides in the regulation of feeding 
responses to microbial products such as LPS is not yet fully understood, but a number of 
cytokine-neuropeptide interactions have been proposed (Langhans, 2007).  IL-1β has 
been implicated in interactions with two specific neuropeptides, neuropeptide Y (NPY) 
and corticotrophin releasing factor (CRF).  NPY is a potent orexigenic or feeding-
stimulating neuropeptide (Sahu et al., 1988) and it has been suggested that IL-1β can 
modulate feeding by reducing hypothalamic NPY levels (Langhans & Hrupka, 1999).  In 
support of the involvement of CRF, a known anorexigenic neuropeptide (Uehara et al., 
1989), as a cytokine-induced mediator of anorexia during infection, are the findings that 
hypothalamic CRF mRNA was increased following i.p. injection of IL-1β (Suda et al., 
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1990) and anorexia induced by IL-1β was attenuated by i.c.v. administration of a CRF 
antagonist (Uehara et al., 1989).  
 
1.3.6.3 Neurotransmitters 
 
Serotonin and histamine are components of important neurotransmitter systems involved 
in the control of feeding.  Administration of IL-1β, TNF-α and IL-6 have been shown to 
increase central serotonergic (5-HT) activity known to decrease food intake (Gemma et 
al., 1991; Zalcman et al., 1994; Clement et al., 1997; Wang & Dunn, 1999) and 
pretreatment with a highly-specific 5-HT2C receptor antagonist blocked the anorexia 
induced by both peripheral and central injections of LPS or IL-1β in rats (von Meyenburg 
et al., 2003a, b; Asarian et al., 2007).   Unlike serotonin, the involvement of histamine as 
a downstream mediator of cytokines in LPS-induced anorexia has not yet been 
investigated.  The findings in rats that changes in neuronal histamine modulate feeding 
behaviour (Ookuma et al., 1993) and that peripheral administration of IL-1β increases the 
hypothalamic histamine turnover rate (Kang et al., 1995), has lead some to hypothesize 
that IL-1β could be inhibiting feeding during infection by increasing the synthesis and 
release of histamine in the hypothalamus (Plata-Salaman, 1998a). 
 
1.4 Cytokines as mediators of lethargy induced by LPS 
 
Not only may sick individuals experience a fever and have little interest in eating food 
but they also may feel lethargic.  Lethargy is a state of hypoactivity characterized by a 
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general feeling of fatigue and an unwillingness to perform normal daily routine activities 
(Hart, 1988).  As with the febrile and anorexic responses of the host to infection, it has 
been proposed that inactivity during infection may be a valuable response, which also is 
aimed at supporting the immunological response of the host to eliminate the pathogen 
(Hart, 1988).  By engaging in less muscular activity the energy reserves which are needed 
for the increased metabolic costs of fever are conserved (Hart, 1988).  Moreover, by 
resting and not moving around, less heat is lost via convection, which aids the heat 
production required for the fever response (Hart, 1988).  It is likely that cytokines could 
mediate the lethargy experienced during infection, as administration of cytokines 
increases the sensation of fatigue reported by healthy human subjects at rest (Spath-
Schwalbe et al., 1998) and reduces general locomotor activity in rats (Schöbitz et al., 
1995; Montkowski et al., 1997). 
 
1.4.1 Interleukin-1β and interleukin-6 
 
Although limited, there is some evidence which implicates IL-1β as a possible mediator 
of lethargy.  Central administration of IL-1β in rats decreases locomotor activity 
(Montkowski et al., 1997) and the time to fatigue during forced treadmill running 
(Carmichael et al., 2006).  In support of IL-6 as a mediator of lethargy are the findings 
that: (i) central administration of IL-6 decreases locomotor activity in rats (Schöbitz et 
al., 1995), (ii) administration of human recombinant IL-6 induces a sensation of fatigue 
in healthy humans at rest (Spath-Schwalbe et al., 1998), (iii) treatment with IL-6 
antibodies induces an immediate disappearance of previously debilitating fatigue reported 
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by patients with multicentric Castleman disease, a disease characterized by a 
dysregulated overproduction of IL-6 (Nishimoto et al., 2000; Nishimoto et al., 2005) and 
(iv) fatigue in patients with cancer is positively correlated with circulating levels of IL-6 
(Schubert et al., 2007).  Despite the above reports from studies showing that IL-1β and 
IL-6 can induce fatigue and decrease activity levels, there has been no evidence to 
support the involvement of either of these two cytokines in mediating the lethargy 
induced in response to microbial products such as LPS.  Mice genetically deficient in IL-
1β or the IL-1 type I receptor demonstrated similar reductions in locomotor activity 
following systemic administration of LPS as did wild-type mice (Kozak et al., 1995b; 
Leon et al., 1996). 
 
1.4.2 Tumour-necrosis factor 
 
In contrast to the lack of evidence in support of the involvement of IL-1β and IL-6 in 
mediating the lethargy induced in response LPS, there have been some, albeit 
contradictory, reports suggesting a role for peripherally-released TNF-α in mediating 
LPS-induced lethargy.  Pre-treating rats and mice with TNF-α inactivating agents 
(antiserum to TNF-α or a TNF soluble receptor) did not prevent the decrease in 
locomotor activity induced by LPS, but did seem to facilitate a faster recovery to normal 
activity levels (Kozak et al., 1995a).  In contrast, others have found that LPS-induced 
lethargy is not attenuated in rats treated with a TNF-binding protein (Töllner et al., 2000) 
or mice which lack functional TNF-α receptors (Leon et al., 1997). 
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1.4.3 The relative contributions of cytokines released in the periphery and the brain in  
         mediating LPS-induced lethargy 
 
Table 3 is a summary of the research findings discussed in the sections above where the 
role of cytokines in mediating lethargy induced by systemic administration of LPS were 
investigated using techniques which allowed selective inhibition or blockade of cytokine 
actions or effects.  These studies investigating LPS-induced lethargy have quantitatively 
assessed the hypoactivity, characteristic of a state of lethargy, in rats and mice by 
measuring general locomotor activity of the experimental animal in its home cage.  The 
research findings presented in Table 3 appear to reflect the complexity of the interactions 
between cytokines and/or other molecules in mediating lethargy during illness, lethargy 
induced by systemic administration of LPS is mostly not affected by the absence of IL-1β 
and TNF-α.  Whilst important, these studies, as with those investigating LPS-induced 
anorexia, have only used an experimental animal model of systemic infection to 
investigate the role of cytokines in mediating LPS-induced lethargy.  Moreover, the 
investigations have not comprehensively investigated all the likely cytokine mediators.  
IL-6 has been implicated as a putative mediator of lethargy in an animal model of 
localized inflammation induced by turpentine (Kozak et al., 1997a).  What, if any, 
involvement IL-6 may have in mediating lethargy induced during a localized Gram-
negative bacterial infection is unknown. 
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Table 3. The effect of antagonizing the action of cytokines released in the periphery and the brain on lethargy induced by LPS 
 
 Lethargy LPS dose and route Animal species References 
Interleukin-1β     
IL-1β knockout mice ▬ 2500 µg kg-1, i.p. Mice Kozak et al., 1995b 
IL-1 type I knockout mice ▬ 50 µg kg-1, i.p. Mice Leon et al., 1996 
IL-1 type I knockout mice ▬ 2500 µg kg-1, i.p. Mice Leon et al., 1996 
 
    
Tumour necrosis factor-α     
Peripheral administration of:     
TNF-α antibodies Attenuated  2500 µg kg-1, i.p. Mice Kozak et al., 1995a 
TNF-binding protein ▬ 5000 µg kg-1, i.p. Rats Töllner et al., 2000 
TNF-α soluble receptors Attenuated 2500 µg kg-1, i.p. Mice Kozak et al., 1995a 
     
TNF double-receptor knockout mice ▬ 50 µg kg-1, i.p. Mice Leon et al., 1997 
TNF double-receptor knockout mice ▬ 2500 µg kg-1, i.p. Mice Leon et al., 1997 
 
i.p. = intraperitoneal  
▬ = no effect 
Studies of the present thesis are excluded from this table 
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1.5 Mechanisms of action by which peripherally-released cytokines signal the brain 
 
From the discussions in the sections above there is significant evidence that cytokines 
present in the circulation can act as important humoral mediators of the brain-controlled 
fever mechanism.  Figure 2 below shows a schematic presentation of the three proposed 
humoral mechanisms by which signalling between cytokines present in the circulation 
and the brain can occur. 
 
 
 
Figure 2.  Schematic presentation of the three proposed humoral mechanisms by which 
circulating cytokines, synthesized in response to peripheral administration of LPS, can 
signal the brain: (A) carrier-mediated transport across the blood-brain barrier (BBB), (B) 
access through the circumventricular organs (CVOs), and (C) synthesis of prostaglandin-
E2 (PGE2) in cells forming the BBB.  Abbreviations: pro-inflammatory cytokines (▲), 
cyclooxygenase-2 (COX-2), cytokine receptor (  ), PGE2 (○). 
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On the one hand, there is experimental evidence which has identified distinct carrier-
mediated transport mechanisms to chaperone cytokines, including TNF-α (Osburg et al., 
2002), IL-1β (Banks et al., 1989; Banks et al., 1993), IL-6 (Banks et al., 1994) and leptin 
(Banks & Lebel, 2002), from the blood to the brain.  The physiological significance of 
carrier transport across the blood brain barrier (BBB) has however, been questioned due 
to the finding that this system transports less than 0.3% of the cytokines present in the 
blood into the central nervous system (Elmquist et al., 1997; Cartmell & Mitchell, 2005).  
The reason for this small proportion appears to be because these transport mechanisms 
are very slow and easily saturable (Conti et al., 2004).  The concentrations of TNF-α and 
IL-1β in the circulation do not usually exceed 100 pg mL-1 in patients during a nonfatal 
infectious episode (Rothwell et al., 1996).  In contrast plasma concentrations of IL-6 can 
often reach 10-20 µg mL-1 during fever in experimental animals and in humans (Rothwell 
et al., 1996).  Although it may allow significant quantities of IL-6 to enter the brain, it is 
unlikely that the carrier-mediated transport of peripherally-released TNF-α and IL-1β 
across the BBB is the primary mechanism by which these two cytokines signal the brain 
to evoke fever and sickness behaviour.  During chronic infection however, when 
endogenous cytokines are elevated for extended periods of time in the circulation or when 
the BBB is breached, direct entry of these circulating cytokines may be of greater 
physiological importance (Elmquist et al., 1997; Cartmell & Mitchell, 2005). 
 
An alternative humoral pathway is the access of cytokines through the circumventricular 
organs (CVOs), a specialized neural region along the margins of the ventricular system 
that has fenestrated capillaries and therefore no blood-brain barrier (BBB).  The absence 
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of a BBB for these CVOs enables cytokines in the circulation to come into contact with 
the cells of the CVOs (Quan & Banks, 2007).  It is possible that cytokines in the 
circulation may enter the perivascular space passively and interact with specific receptors 
located on the surface of glial cells, perivascular macrophages or endothelial cells.  These 
cells may produce additional pro-inflammatory cytokines or secondary mediators such as 
PGE2, which would act directly or indirectly on neurones that project to other brain 
structures or disseminate into adjacent brain parenchyma by volume diffusion (Komaki et 
al., 1992; Roth et al., 2004a; Rummel et al., 2005b).  In addition to cytokines in the 
circulation acting on the CVOs, the observation that endothelial cells in the CVOs also 
constitutively express CD14 and TLR4 means that it is possible that bacterial fragments 
themselves can induce the synthesis of pro-inflammatory cytokines at the level of the 
CVOs (Laflamme & Rivest, 2001).   
 
The two mechanisms discussed thus far, have mainly focused on cytokines present in the 
circulation having to gain access to the brain tissue itself to be able to signal 
thermoregulatory neurones.  Over the last ten years another mechanism whereby 
cytokines present in the circulation do not actually have to gain access to the brain tissue 
to signal thermoregulatory neurones, but rather they can mediate the induction of 
cytokine synthesis and other signalling molecules within cells of the BBB, which can 
then penetrate into the brain tissue, has gained prominence (Quan & Banks, 2007).  
Endothelial cells of cerebral microvasculature constitutively express receptors for TNF-α 
(Nadeau & Rivest, 1999) and IL-1 (Konsman et al., 2004), with the receptor for IL-6 
being expressed under inflammatory conditions (Vallieres & Rivest, 1997).  Peripheral 
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administration of LPS, IL-1β, TNF-α and IL-6 has been shown to induce genomic 
activation of the brain endothelium leading to the expression of COX-2, which is required 
for the formation of PGE2 (Cao et al., 1996; Yamagata et al., 2001; Nadjar et al., 2003; 
Rummel et al., 2005a; Rummel et al., 2006).  The notion that endothelial cells can 
interact with circulating cytokines to release additional cytokines, or secondary mediators 
such as PGE2, therefore not only applies to the sensory CVOs, but the entire brain 
endothelium (Roth et al., 2006). 
 
In addition to the three humoral pathways by which inflammatory challenges in the 
periphery can communicate with the brain, an alternative rapid signalling neural pathway, 
possibly involving cutaneous and vagal neural signals, which functions independently of 
circulating cytokines, has also been proposed (Bluthé et al., 1994b; Blatteis & Sehic, 
1997; Ross et al., 2000).  The role of the vagus nerve in the transmission of information 
from the periphery to the brain has been assessed by vagotomy experiments in which the 
vagus nerve is sectioned under the diaphragm.  Subdiaphragmatic vagotomy resulted in 
an attenuation of the fever response only when LPS was administered at a low dose 
(Romanovsky et al., 1997) and via the i.p. route (Goldbach et al., 1997).  In terms of 
mediating sickness behaviours, attenuated responses with subdiaphragmatic vagotomy 
also appeared to be specific to the abdominal cavity (an i.p. injection), because vagotomy 
did not attenuate the behavioural effects of IL-1β when this cytokine was injected by 
either the s.c. or i.v. routes (Bluthé et al., 1996).  When activated by peripheral cytokines 
the vagus appears to be able to activate specific neural pathways in the brain which are 
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involved in fever and sickness behaviour and to stimulate microglia in the brain to 
produce cytokines (Layé et al., 1995; Bluthé et al., 1996; Roth et al., 2006). 
 
Having established that vagal afferents may be involved in mediating the effects of 
peripheral cytokines under some experimental conditions, the question arose as to 
whether this response was specific to afferent neural signals from the viscera.  To block 
the signals of cutaneous afferents induced by LPS injection into an air pouch, an 
experimental model of localized subcutaneous inflammation, a local anaesthetic was co-
administered with the LPS.  Using this experimental approach it was found that 
cutaneous afferents, as with vagal afferents, contribute as a communication pathway to 
the brain, but again only when low (10 µg kg-1) and not high (100 µg kg-1) doses of LPS 
are administered (Ross et al., 2000).  A possible explanation for the apparent lack of 
involvement of neural signals when LPS is administered at high doses could be that these 
doses induce a greater increase in circulating cytokines, known humoral mediators, which 
can override the lack of a neuronal signal (Roth & De Souza, 2001). Although the relative 
importance of these different humoral and neural pathways by which peripherally-
released cytokines can communicate with the brain remains an area of much debate, it is 
accepted that cytokines synthesized in the periphery are an important pathway for 
communication to the brain during a peripheral immune challenge. 
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1.6 Thesis aims 
 
Having reviewed all the studies investigating the roles of endogenous IL-1β, IL-6, TNF-α 
and leptin in mediating fever induced by systemic and local administration of LPS in the 
sections above, it is evident that peripherally-released cytokines, in particular IL-6, are 
important endogenous mediators in the fever pathway.  In contrast, although it has been 
shown that systemic administration of pyrogenic cytokines can induce anorexia and 
lethargy in experimental animals, no clear role has been identified for these cytokines as 
endogenous mediators of anorexia and lethargy induced following systemic and local 
administration of LPS.  Using proven techniques and highly quantifiable measures of 
each response I therefore set out to try and clarify the role of endogenous pyrogenic 
cytokines in mediating anorexia and lethargy induced following local subcutaneous (s.c.) 
administration of LPS.  All the measurements were recorded concurrently, as not only did 
I investigate the contribution of cytokines in mediating each of the individual sickness 
responses (anorexia, lethargy and fever), but I also investigated if their involvement 
differed between responses.  Core body temperature was measured using temperature-
sensitive radiotransmitters which were implanted intra-abdominally and anorexia was 
assessed by measuring the quantity of food consumed over a specified time period.  
These are both proven measurements techniques which provide highly quantifiable 
measures of core body temperature and anorexia.  In terms of lethargy, researchers have 
traditionally measured changes in general locomotor activity of an experimental animal in 
its home cage to identify whether the animal is lethargic or not.  The lethargy 
accompanying illness, however, not only results in an unwillingness of the individual to 
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perform normal daily routine activities, but also to engage in physical exercise.  When 
running wheels are attached to the cages of experimental animals such as rats and mice, 
they willingly engage in spontaneous physical exercise.  Challenging mice with 
Corynebacterium parvum or Brucella abortus antigen has been shown to reduce 
voluntary wheel-running (Sheng et al., 1996; Ottenweller et al., 1998; Sheng et al., 
2001).  Voluntary-wheel running and general locomotor activity (measured as cage 
activity) are both therefore appropriate measures of lethargy during infection.  It has been 
noted however, that suppression of voluntary exercise is a more sensitive measure of 
fatigue and lethargy induced by LPS, than is suppression of cage activity.  Voluntary-
wheel running of rats, for example, is almost completely abolished by a single i.p. 
injection of LPS (75 µg kg-1) whereas cage activity is only decreased by ~50% (Hopwood 
and Harden unpublished observations).  I therefore chose to use voluntary wheel-running 
as a highly quantifiable and sensitive measure of lethargy for the studies presented in 
Chapters 2, 3, and 4. 
 
The findings presented in Tables 1, 2 and 3 from studies investigating the involvement of 
cytokines in mediating LPS-induced fever and anorexia, highlighted that acute 
pharmacological or immunological antagonism of cytokines has generally proven to be a 
more physiological and successful approach to use when investigating the contribution of 
individual cytokines in mediating specific sickness responses, rather than genetic ablation 
of a particular cytokine or its receptor.  The interpretation of the findings from knockout 
mice have often proven to be problematic, as for a particular gene knockout mouse to 
survive to adulthood it is likely that compensatory mechanisms would have had to 
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develop to enable the mouse to cope with the loss of the deleted cytokine’s action.  In the 
studies presented in Chapters 2 and 4 I therefore specifically chose to use 
pharmacological or immunological antagonism of cytokines to determine the relative 
involvement of individual cytokines in mediating the sickness responses induced 
following LPS administration. 
 
1.6.1 Aim 1 
 
Of the pro-inflammatory cytokines released by immune cells following systemic and 
local administration of LPS, IL-6 has emerged as an important circulating mediator of the 
fever response (Cartmell et al., 2000). Another cytokine-like hormone, leptin, also 
apparently plays a role in LPS-induced fever and anorexia in rats (Sachot et al., 2004).  
However, whether these or other peripherally-released cytokines are involved in the 
lethargy observed following s.c. administration of LPS remains uncertain.  The aim of 
the experiments presented in Chapter 2 was therefore to examine whether the LPS-
induced release of the cytokines, IL-1β, IL-6, TNF-α and leptin in the periphery is 
involved in mediating lethargy, anorexia and fever in rats.  To determine the 
involvement of each of these cytokines I antagonized their action following LPS 
administration by administering species-specific antisera to each individual cytokine 
peripherally.  Lethargy, anorexia and fever were measured as changes in voluntary 
wheel-running, food intake and body temperature respectively.  I found, as have others, 
that the LPS-induced fever in rats was abolished if either IL-6 or leptin antisera were 
administered before LPS.  In addition, I showed for the first time that peripherally-
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released IL-6 plays a role in the suppression of voluntary activity, as well as in the 
suppression of food intake induced by s.c. administration of LPS.  The voluntary activity 
and food intake observed after the administration of the IL-6 antiserum was however, 
unlike the fever response, reduced but not abolished.  It would appear therefore, that 
while peripherally-released IL-6 has a critical role to play in the events regulating fever, 
an additional factor(s), possibly other cytokines, are working in parallel with IL-6 to 
regulate the lethargy and anorexia induced by LPS. 
 
1.6.2 Aim 2 
 
As shown in chapter 2 and by others (Kent et al., 1992b; Kozak et al., 1995b; Leon et al., 
1996; Leon et al., 1997; Swiergiel & Dunn, 1999; Töllner et al., 2000) antagonizing the 
action of other peripherally-released cytokines, TNF-α and IL-1β, has no effect on 
lethargy and anorexia in rats and mice during infection and inflammation.  Thus it 
appeared likely that if other cytokines are working in conjunction with peripherally-
released IL-6 to induced lethargy and anorexia it is primarily due to their action within 
the brain.  The first aim of the experiments presented in Chapter 3 was therefore to 
determine the direct effects of injecting IL-1β and IL-6 into the brain, on voluntary 
wheel-running, food intake and body temperature in rats.  The observation that no 
single cytokine appears to regulate the responses of anorexia and lethargy induced by 
LPS, has lead to the proposal that interactions between cytokines are required to affect 
food intake and voluntary activity following LPS administration.  In particular, cytokine 
interactions observed as physiological synergy, in which the effect of a combination of 
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substances exceeds the effect of the individual constituents, has been demonstrated in 
vivo (Bluthé et al., 1994a; Sonti et al., 1996; Lenczowski et al., 1999).  The second aim 
of the experiments presented in Chapter 3 was to assess whether IL-6 and IL-1β act 
synergistically within the brain to mediate changes in voluntary activity, food intake 
and body temperature.  I injected species-homologous rat IL-6 and IL-1β separately 
and in combination, into the brains of conscious rats and examined the dose-response 
effects.  I found that i.c.v. administration of species-homologous rat IL-6 and IL-1β on 
their own before the night-time active period decreases voluntary activity and also 
increases body temperature in rats in a dose-dependent fashion.   While i.c.v. 
administration of both IL-1β and IL-6 decreased voluntary activity, only IL-1β 
administration decreased food intake.  Moreover, I identified new findings regarding the 
synergistic relationship between IL-1β and IL-6 in the brain, by showing that central co-
administration of doses of IL-1β and IL-6 which, when injected on their own were non-
pyrogenic and did not affect food intake and body mass, induced fever and anorexia when 
they were co-injected centrally.  It would appear that the synergistic action of IL-1β and 
IL-6 in the brain is not inevitable however, as I did not observe a synergistic effect on the 
suppression of voluntary wheel-running when both cytokines were co-injected. 
 
1.6.3 Aim 3 
 
From the findings obtained in the studies presented in chapters 2 and 3, I hypothesized 
that endogenous brain IL-1β is the likely central cytokine, working in parallel with IL-6 
released in the periphery, to induce anorexia and lethargy following s.c. administration of 
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LPS.  The aim of the experiments presented in Chapter 4 was therefore to determine 
the relative contribution of both peripherally-released IL-6 and centrally released 
IL-1β in mediating the lethargy, anorexia and fever induced by s.c. administration 
of LPS in rats.  To decrease the biological activity of IL-6 in the circulation and IL-1β in 
the brain I administered species-specific antiserum to IL-6 i.p. and a caspase-1 inhibitor, 
shown to prevent the cleavage of pro-IL-β to biologically active IL-1β, i.c.v.  I found that 
both peripherally-released IL-6 and IL-1β in the brain are involved in the induction and 
maintenance of LPS-induced lethargy and anorexia, and confirmed that circulating IL-6 
is the primary endogenous pyrogen mediating LPS-induced fever. 
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ABSTRACT 
Although fever, anorexia and lethargy may be beneficial sickness responses initially, they 
may become detrimental to the host if they continue for a prolonged period.  We 
therefore investigated whether antagonizing the biological action of putative mediators of 
these sickness responses, interleukin (IL)-6 and IL-1β, could affect the duration of 
anorexia, lethargy and fever, measured as changes in food intake, voluntary activity and 
body temperature, induced by subcutaneous (s.c.) administration of lipopolysaccharide 
(LPS).  Male Sprague-Dawley rats were randomly assigned to receive a caspase-1 
inhibitor to reduce the synthesis of IL-1β or vehicle intracerebroventricularly and 
antiserum to IL-6 (IL-6AS) or pre-immune serum intraperitoneally, before receiving an 
injection of LPS (250 µg/kg) or saline.  LPS administration induced a ~1.3 ± 0.2 ºC fever 
and reduced voluntary activity by 98.0 ± 2.4 %, food intake by 50.0 ± 9.8 % and body 
mass by 14.5 ± 2.7 g compared to rats injected with saline (P < 0.05, ANOVA).  
Increases in plasma IL-6 and IL-1β accompanied LPS administration on the day of 
injection.  Within 2 days the fever resolved, while lethargy and anorexia continued for at 
least 3 days.  Rats pre-treated with IL-6AS had reduced plasma levels of bioactive IL-6, 
no fever and attenuated sickness behaviors which resolved within 2 days.  Rats pre-
treated with the caspase-1 inhibitor exhibited attenuated fever and sickness behaviors 
which resolved within 2 days.  Thus antagonizing the biological action of IL-6 in the 
circulation or IL-1β in the brain significantly reduces the duration of anorexia, lethargy 
and fever induced by LPS administration. 
Keywords: Voluntary wheel-running; Anorexia; Pro-inflammatory cytokines 
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1. Introduction 
 
Fever and sickness behaviors, such as anorexia and lethargy, experienced during infection 
appear to be advantageous short-term responses intended to support the immunological 
response of the host to eliminate the pathogen [18].  Although the feeling of fatigue, loss 
of appetite and increase in body temperature may be beneficial responses acutely, 
experiencing these sickness responses on a daily basis for prolonged periods may 
negatively impact the quality of life of patients and even worsen their condition, 
ultimately delaying recovery [19, 55].  From a clinical point of view identifying the 
physiological mechanisms underlying the onset and maintenance of these sickness 
responses during illness is particularly relevant because it may enable the design of 
appropriate therapeutic interventions to oppose the detrimental effects of the prolonged 
duration of sickness responses [23]. 
 
Most experimental investigations examining the physiological mechanisms mediating 
fever and sickness behavior responses have used purified lipopolysaccharide (LPS), the 
glycolipid pyrogenic moiety of the Gram-negative bacterial membrane, to trigger the 
innate immune system [9].  Part of the innate immune systems response to the presence 
of endotoxin in animals and humans includes the synthesis and release of pro-
inflammatory cytokines from immune cells [13].  Results obtained from studies using 
specific antagonists to block the action of these cytokines released into the circulation 
following systemic administration of LPS, have uncovered a critical role for one 
particular cytokine, interleukin (IL)-6, in mediating the physiological response of fever 
[10, 16].  Although fever and sickness behavior both occur after systemic administration 
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of LPS, it has been established that these behavioral and febrile responses are not 
mediated via exactly the same cytokine-induced mechanisms [16, 24].  In particular, 
results from a study conducted within our laboratory showing that neutralizing the 
biological activity of IL-6 in the circulation completely abolishes fever, but only partially 
attenuates sickness behaviors, has identified one such distinct difference in the cytokine 
mechanisms mediating fever and sickness behavior [16].  It would appear therefore, that 
while IL-6 released in the periphery has a critical role to play in the events regulating 
fever, additional factors, possibly other cytokines, work in parallel with peripherally 
released IL-6 to regulate the sickness behavior responses induced by systemic 
administration of LPS.  There is evidence to suggest that if other cytokines are working 
with peripherally released IL-6 to induce sickness behaviors, and two likely candidates 
are IL-1β and TNF-α [22], it is due primarily to their synthesis in the brain and not in the 
periphery, because antagonizing the actions of IL-1β and TNF-α in the periphery has 
been shown to have no effect on lethargy and no or minimal effect on anorexia induced in 
rats and mice during infection and inflammation [6, 16, 25, 27, 31, 32, 35, 48, 56]. 
 
Several studies have demonstrated that rats and mice treated intracerebroventricularly 
(i.c.v.) with IL-1β and TNF-α exhibit symptoms similar to those of LPS-treated animals, 
suggesting that both cytokines may be important central mediators of LPS-induced 
sickness behaviors [5, 17].  There are several lines of evidence to however suggest, that 
IL-1β mediates the synthesis and behavioral effects of TNF-α in the brain, because 
injecting IL-1 receptor antagonist (IL-1ra) i.c.v. has been shown to: (i) abrogate the 
mRNA expression of not only IL-1β but also TNF-α in the hypothalamus of mice 
injected peripherally with LPS [30] and (ii) to inhibit the behavioral effects of centrally 
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administered TNF-α [5].  It is reasonable to hypothesize therefore that endogenous brain 
IL-1β is the likely central cytokine working in parallel with IL-6 released in the periphery 
to induce sickness behavior following systemic administration of LPS.  Although 
peripherally-released IL-6 has been implicated in mediating the development of LPS-
induced sickness behaviors [4, 53], the involvement of IL-1β in the brain in mediating the 
development of LPS-induced sickness behaviors has not yet clearly been established [3, 
25, 30].  Moreover the extent to which the absence of either of these cytokines affects the 
resolution of LPS-induced sickness behaviors has also not been established. 
 
Thus we have chosen to antagonize the biological action of peripherally-released IL-6 or 
IL-1β in the brain following subcutaneous injection of LPS, and to monitor the behavioral 
responses until the symptoms of sickness induced by LPS have ceased, so as to determine 
the cytokine involvement not only in the induction of these responses, but also in their 
resolution.  In particular we chose to decrease the biological activity of IL-6 in the 
circulation and IL-1β in the brain by administering species-specific antiserum to IL-6 (IL-
6AS) intraperitoneally and a caspase-1 inhibitor, which prevents the cleavage of pro-IL-β 
to biologically active IL-1β, intracerebroventricularly.  We monitored quantifiable 
behavioral responses known to be affected by systemic administration of LPS, such as 
food intake and voluntary wheel-running.  Moreover, we measured body temperature to 
assess whether differences exist between the involvement of IL-6 in the periphery and IL-
1β in the brain in mediating fever and sickness behavior.  Our results reveal that 
antagonizing the biological action of IL-6 in the circulation or IL-1β in the brain 
significantly reduces the duration of anorexia, lethargy and fever induced by s.c. LPS 
administration.  
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2. Methods 
 
2.1 Animals 
Male Sprague-Dawley rats (initial body mass 80 - 120 g) were housed individually in 
cages to which exercise-training wheels had been attached.  The rats were kept at an 
ambient temperature of 21 ± 2°C on a reversed 12 h:12 h light:dark cycle (lights on from 
22:30 - 10:30).  The light:dark cycle of the rats was reversed over a period of four weeks 
before the rats underwent surgery (described below).  That the rats’ circadian rhythm had 
been 12-h shifted, was confirmed before the start of the experimental interventions by 
evidence of a normal nychthemeral temperature rhythm for each rat.  Food (pelleted rat 
chow, Epol, Johannesburg, South Africa) and water were provided ad libitum.  All 
procedures were in accordance with the Animal Ethics and Control Committee of the 
University of the Witwatersrand animal care regulations and were approved by the 
Animal Ethics Screening Committee of the University of the Witwatersrand (ethics no 
2005/86/5). 
 
2.2 Surgery 
Rats selected for the study (body masses 280 - 320 g) were anesthetized with an 
intramuscular (i.m.) injection of 80 mg/kg ketamine hydrochloride (Anaket-V, Bayer, 
SA) and 20 mg/kg xylazine (Chanazine, Bayer, SA) and had a temperature-sensitive 
radiotransmitter (TA10TA-F40, Data Sciences, St. Paul, MN, USA) implanted 
intraperitoneally.  Thereafter the rats were placed in a stereotaxic frame (Stoelting, IL, 
USA), a heating pad was placed beneath the animal to maintain core body temperature 
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and they were given an injection (0.1 ml) of adrenaline (10 µg) (Merck, SA) and 
lignocaine hydrochloride (0.02 g) (Bayer, SA) subcutaneously over an area of skull.  An 
incision was made in the midline of the cranium to expose the skull.  A 23-gauge 
stainless steel guide cannula (Plastics One, Roanoke, VA, USA) was placed over the right 
lateral cerebral ventricle.  Coordinates for the guide cannula were 0.8 mm posterior to 
bregma,  1.5 mm lateral to the midline and 3.5 mm below the skull surface at the point of 
entry of the guide cannula [39].  The cannula was secured to the skull with three screws 
and dental cement.  After surgery each rat was given a subcutaneous injection of 0.3 mg 
buprenorphine hydrochloride (Temgesic, Schering-Plough, SA) and ringer lactate (1.5 
ml) (SABAX, Adcock, Ingram, SA). 
 
2.3 Body temperature 
Core body temperatures of rats were measured by remote biotelemetry using temperature 
-sensitive radiotransmitters which had been implanted intraperitoneally (see above). 
Transmitter output frequency (Hz) was monitored at five minute intervals, by a receiver 
plate (RTA 500, Mini-Mitter, Sunriver, OR, USA) situated beneath the cage of each 
animal.  The frequency received by each plate was fed into a peripheral processor (DP-24 
DataPort, VitalView, Minimitter, Sunriver, OR, USA) connected to a personal computer 
and the output expressed in degrees centigrade.  The telemeters were calibrated by water 
immersion against a high-accuracy thermometer (Quat 100, Heraeus, Germany) to an 
accuracy of 0.1°C. 
 
 
 86 
2.4 Voluntary wheel-running 
The exercise-training wheels had a circumference of 1.06 m and each wheel was 
equipped with a magnet and a magnetic switch (VitalView, Minimitter, Sunriver, OR, 
USA).  Each time the wheel rotated the magnet within range of the magnetic switch, the 
switch closed and a turn was counted.  The magnetic switches were connected to an 
activity input module (QA-4, VitalView, Minimitter, Sunriver, OR, USA) which in turn 
was fed  into a peripheral processor (DP-24 DataPort, VitalView, Sunriver, OR, USA) 
connected to a personal computer which monitored the number of wheel turns at five 
minute intervals using VitalView software version 4.1 (Mini Mitter, Bend, OR, USA).   
 
2.5 Food intake and body mass 
Food intake and body mass were measured daily just before lights off.  Food containers 
were filled daily with 100 g of standardized pelleted rat chow.  Food intake was 
quantified by subtracting the food remaining in the food container and on the cage floor 
from the amount of food measured at the preceding time point.   
 
2.6 Pyrogens and cytokine antagonists 
Lipopolysaccharide injections 
Lipopolysaccharide (LPS) derived from Escherichia coli endotoxin (serotype 0111:B4, 
Sigma, St. Louis, MO, US) was reconstituted in saline (sterile, pyrogen-free 0.9% saline 
Sabax, Johannesburg, South Africa) and injected subcutaneously (s.c.) at a dose of 250 
µg/kg. 
 
 87 
Cytokine antiserum injections 
We used a species-specific antiserum to IL-6 (IL-6AS, NIBSC, South Mimms, Potters 
Bar, Herts UK) and pre-immune (normal) sheep serum (PIS, lot 056K8408, Sigma, St. 
Louis, MO, US) for the control injections, all with an endotoxin content < 0.24 ng/ml (2.4 
IU).  The IL-6AS and the PIS were injected intraperitoneally (i.p.) in a volume of 1.5 ml.  
The antibodies were raised in sheep as previously described [42, 43].  The IL-6AS used 
recognizes both natural and recombinant (Escherichia coli-derived) rat IL-6, but does not 
cross-react with the following rat recombinant cytokines: (rr) TNF-α, IL-1β, IL-1α, IL-
1ra and IL-10 [42, 43]. 
 
Caspase-1 inhibitor injections 
We used a specific caspase-1 inhibitor Ac.YVAD-cmk (Ac-Tyr-Val-Ala-Asp-
chloromethylketone; lot B75699; Calbiochem, Darmstadt, Germany) to decrease the 
synthesis of IL-1β within the brain.  The caspase-1 inhibitor (300 ng/rat) and the vehicle 
for its injection (0.6% DMSO in sterile saline) were injected intracerebroventricularly 
(i.c.v.) in a volume of 5 µl.  This dose of caspase-1 inhibitor previously has been shown, 
when injected into the brain, to prevent the synthesis of brain IL-1β following i.p. 
administration of LPS [2]. 
 
2.7 Cytokine analysis  
To assess the efficacy of IL-6AS in decreasing the biological activity of IL-6 in the 
periphery, we measured the levels of bioactive IL-6 in plasma using a bioassay.  
Determination of IL-6 was achieved by a bioassay based on the dose-dependent growth 
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stimulation of IL-6 on the B9 hybridoma cell line [1].  The assay was performed in 
sterile, 96-well microtiter plates.  In each well, 5,000 B9 cells were incubated for 72 h 
with serial dilutions of biological samples or with different concentrations of a human IL-
6 standard (code 89/548, National Institute for Biological Standards and Control, South 
Mimms, UK).  The number of living cells after 72 h was measured by using the 
dimethylthiazoldiphenyl tetrazolium bromide (MTT) colorimetric assay [20].   Plasma 
samples were pre-diluted so that serial dilution of samples and standard dilution curves 
were parallel.  The detection limit of the assay, after considering the dilution of samples 
into the assays, was 3 IU of IL-6/ml.  As opposed to ELISA assays, use of the described 
bioassays does not exclude the possibility that some undiscovered substance might 
interfere in the assay by causing proliferation of the B9 cells.  Therefore, we will refer to 
the measured IL-6 as IL-6-like-activity.     
 
To exclude the possibility that trace amounts of the caspase-1 inhibitor injected i.c.v. 
entered the blood from the brain and attenuated the synthesis of IL-1β in the periphery 
following LPS administration, we measured the concentration IL-1β in plasma using a 
commercially available enzyme linked immunosorbent assay (ELISA) kit (R & D 
Systems, Minneapolis, MN).  The microplate used had been pre-coated with an affinity 
purified polyclonal antibody specific for rat IL-1β.  Fifty microliters of standard, control 
or sample was added to each well and incubated for 2 hours at room temperature.  Each 
sample was measured in duplicate.  After washing away any unbound substances, an 
enzyme-linked polyclonal antibody specific for rat IL-1β was added to each well (100 µl) 
and incubated for 2 hours at room temperature.  Following a wash to remove any 
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unbound antibody-enzyme reagent, a substrate solution was added to each well (100 µl) 
and incubated for 30 minutes at room temperature.  The enzyme reaction yielded a blue 
product that turned yellow when the reaction was terminated by addition of 100 µl of 
diluted HCl to each well.  The optical density was measured at 450 nm and 540 nm.  The 
readings obtained at 540 nm were subtracted from the readings obtained at 450 nm and 
the sample values were then read off the standard curve.  The subtraction was used to 
correct for optical imperfections in the plate.  The results were expressed as pg/ml.  The 
detection limit of the assay was 5 pg/ml.  Where the values obtained were below the 
detection limit, the detection limit of the assay was assigned. 
 
2.8 Experimental procedure 
We reversed the light/dark cycle of the rats so as to enable the collection of blood 
samples, describe below, during the day-time.  To ensure that rats used in the experiments 
were exposed to the same experimental conditions, we reversed the light/dark cycle for 
all the rats used in the study.  During the 4 week adaptation period required to reverse the 
light/dark cycle we monitored wheel-running of the rats.  Rats with an average voluntary 
running distance per day (24 h) of 1 km, monitored over this 4-week period were selected 
for experiments.  After surgery for implantation of the radiotransmitters and guide 
cannuale, all animals were returned to their cages and the running wheels were locked for 
a period of seven days so that animals could not exercise.  Thereafter, the wheels were 
unlocked and experimentation started 4 weeks post-surgery once rats had reached their 
pre-surgery daily running distances.  During this post-surgery period the rats were 
habituated to handling and injection procedures.  To confirm correct placement of the 
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guide cannula, two weeks before injections rats were injected i.c.v. with angiotensin II 
(10 ng/5µl; A-2900, Sigma, St. Louis, MO, USA) and then monitored for a drinking 
response for 30 min after the injection.  Rats with a positive drinking response (>10 ml of 
water in 30-min) were used in the study. 
 
For microinjections, a 30-gauge injection stylette (Plastics One, Roanoke, VA, USA), 
connected by polyethylene tubing (0.58 mm i.d., 1.27 mm o.d.) to a 50 µl Hamilton gas-
tight microlitre syringe (Hamilton, Switzerland) was lowered into the guide cannula so 
that it protruded 0.5 mm beyond the tip of the guide cannula into the ventricle.  Each 
microinjection was administered to freely moving rats over a period of 60 s.  The 
injection stylette was left in the guide cannula for an additional 5 min to ensure dispersion 
of the injected substance within the ventricle.  Separate groups of rats were used in 
experiment 1 and experiment 2 described below.  However, rats used in both experiments 
all underwent the same adaptations, surgical and experimental procedures described in 
the paragraphs above. 
 
Experiment 1: Analysis of physiological responses   
Rats received LPS or saline, together with IL-6AS or PIS, together with the caspase-1 
inhibitor or its vehicle.  They were randomly assigned to receive one of the following 
combinations of injections: LPS + PIS + vehicle (n = 8), LPS + IL-6AS + vehicle (n = 7), 
LPS + PIS + caspase-1 inhibitor (n = 8), saline + PIS + vehicle (n = 7), saline + IL-6AS + 
vehicle (n = 6) or saline + PIS + caspase-1 inhibitor (n = 6).  To control for any different 
effects the two control injections (vehicle i.c.v. and PIS i.p.) may have, we chose to 
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include both control injections for all experimental groups.  The caspase-1 
inhibitor/vehicle (i.c.v.) injections and IL-6AS/PIS (i.p.) injections were administered at 
08:00, 2 h before the injections of LPS or saline (s.c.) at 10:00, the latter being 30 min 
before the onset of the dark phase when rats are most active.  Wheel-running, food intake, 
body mass and body temperature were monitored for 72 h before and after the injections. 
 
Experiment 2: Circulating cytokine responses 
Rats were randomly assigned to receive one of the following combinations of injections: 
LPS + PIS + vehicle (n = 9), LPS + IL-6AS + vehicle (n = 8), LPS + PIS + caspase-1 
inhibitor (n = 7) or saline + PIS + vehicle (n = 10).  Having determined in experiment 1 
that neither injections of saline (s.c.) + IL-6AS (i.p.) or saline (s.c.) + caspase-1 inhibitor 
(i.c.v.) affected any of the physiological responses we measured, we chose to include 
only one control group, saline + PIS + vehicle, for experiment 2.  The caspase-1 
inhibitor/vehicle (i.c.v.) injections and IL-6AS/PIS (i.p.) injections were administered at 
08:00, 2 h before the injections of LPS or saline at 10:00, the latter being 30 min before 
the onset of the dark phase.  Based on the observations made by others [10, 33] that the 
increase in IL-6 concentration in plasma following LPS administration peaks at 
approximately the same time as does the increase in body temperature, and our 
observation on the course of fever from experiment 1, we chose to collect plasma samples 
5 h after the s.c. injection of LPS or saline.  Thus, blood was collected by cardiac 
puncture after the injections of LPS or saline from rats under terminal anaesthesia 
induced with an i.m. injection of 80 mg/kg ketamine hydrochloride (Anaket-V, Bayer, 
SA) and 20 mg/kg xylazine (Chanazine, Bayer, SA).  Blood was collected into sterile 
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tubes containing EDTA and centrifuged (5300 g, 4ºC, 10 min).  Following the cardiac 
puncture rats were euthanized by intracardiac injection of 1 ml sodium pentobarbital 
(Euthanase; Kyron, Johannesburg, South Africa).  Plasma was stored at -70ºC until 
assayed. 
 
Correct placement of guide cannulae was verified post mortem by infusion of 5 µl of blue 
dye (Kyro-quick stain, Kyron Laboratories, SA) through the guide cannula assembly.  
After 5 min the brain was removed and placed on ice and the distribution of the ink 
within the ventricles was visually inspected in approximately 1-mm sections of the brain. 
 
2.9 Data analysis 
All data are expressed as mean ± SD.  The body temperature responses were plotted as 
abdominal temperature-time curves in 60 minute intervals.  For statistical purposes, the 
original 5-minute temperature recordings of each rat were averaged over 2 h for the 12-h 
period of darkness (10:30 - 22:30) and 12-h period of light (22:30 - 10:30).  The two-
hourly means were analyzed using two-way analysis of variance with intervention and 
time as main effects.  A Student-Newman-Keul’s (SNK) post hoc test was used to detect 
differences within and between groups when the ANOVA detected significant main 
effects or interactions.  Running distance was determined from the number of wheel turns 
per 24-h period (10:30 - 10:30) and expressed as a percentage change from the mean 
running distance measured over 3 days before the injections.  Food intake was calculated 
as grams of food consumed in 24 h per 100 gram of rat body mass (measured daily) and 
expressed as a percentage change from the mean daily food intake measured over 3 days 
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before the injections.  Change in body mass was determined by subtracting the body mass 
measured on each of the 3 days after the injection from the body mass measured 
immediately prior to injection. The change in wheel-running, food consumption and body 
mass between experimental groups for each of the days after injection was analyzed using 
a one-way analysis of variance followed by a SNK post hoc test.  To determine whether 
the change in wheel-running, food intake and body mass on each of the 3 days post 
injection was significantly different from pre-injection values, a one sample t test was 
performed for each of the experimental groups.  Because the values for cytokine 
concentrations are not normally distributed, a log transformation of the cytokine values 
was performed before the data were analyzed using a one-way ANOVA followed by a 
SNK post hoc test. 
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3. Results 
 
3.1 Experiment 1: Three-day analysis of physiological responses 
In this experiment body temperature, voluntary-wheel running, food intake and body 
mass were monitored for 3 days after rats were treated according to the triple-injection 
protocol (i.p. and i.c.v. injections followed 2 h later with an s.c. injection) described in 
the methods section.  For the sake of brevity, the six different experimental conditions 
will be identified in the results section below as follows: 
LPS (250 µg/kg s.c.) + PIS (1.5 ml i.p.) + veh (5 µl i.c.v.) = LPS alone; 
LPS (250 µg/kg s.c.) + IL-6AS (1.5 ml i.p.) + veh (5 µl i.c.v.) = LPS + IL-6AS; 
LPS (250 µg/kg s.c.) + PIS (1.5 ml i.p.) + casp-inh (300 ng/5 µl i.c.v.) = LPS + casp-inh; 
Saline (s.c.) + PIS (1.5 ml i.p.) + veh (5 µl i.c.v.) = saline alone; 
Saline (s.c.) + IL-6AS (1.5 ml i.p.) + veh (5 µl i.c.v.) = saline + IL-6AS;  
Saline (s.c.) + PIS (1.5 ml i.p.) + casp-inh (300 ng/5 µl i.c.v.) = saline + casp-inh.  
 
Body temperature 
Fig. 1 shows that s.c. injection of LPS induced a significant rise in body temperature after 
a latent period of ~ 3 h.  The body temperature of rats injected with LPS peaked at 39.5 ± 
0.3°C between 5 and 7 h after the injection and remained significantly elevated for 8 h 
during the first lights off period after injection in comparison to rats injected with saline 
(the main effects of time (F(5,130)   =  39.2 , P < 0.0001), group (F(3,26)   =  19.2 , P < 
0.0001) and interaction (F(15,130)   =  5.1 , P < 0.0001)).   On day 1 the body temperature 
of rats injected with LPS remained elevated for the entire 12 h light period also, 
 95 
compared to the body temperature of rats injected with saline (the main effects of time 
(F(5,130)   =  14.4 , P < 0.0001), group (F(3,26)   =  20.7 , P < 0.0001) and interaction 
(F(15,130)   =  0.9 , P  > 0.05)). With lights off at the end of day 1 the body temperatures of 
rats injected with LPS remained at a similar level to that during the lights on period on 
day 1, while the body temperatures of the rats that received saline continued to follow a 
circadian rhythm and increased sharply with lights off.  As such there was no significant 
difference between the body temperatures of rats injected with saline and LPS over the 
lights off period on day 2.  With lights on, on day 2, the body temperatures of rats 
injected with saline and LPS both decreased.  However, the body temperatures of rats 
injected with LPS remained slightly elevated for most of the lights on period (6 h) 
compared to the body temperatures of rats injected with saline (the main effects of time 
(F(5,130)   =  22.5 , P < 0.0001), group (F(3,26)   =  9.1 , P < 0.001) and interaction (F(15,130)   
=  1.9 , P < 0.05).  During day 3 after the injections the circadian rhythm of body 
temperature for rats injected with LPS and saline was similar. 
 
Fig. 2A shows that pre-treating rats i.p. with IL-6AS completely abolished the LPS-
induced fever (P < 0.01, SNK), such that the circadian rhythm of body temperature of 
rats injected with LPS + IL-6AS were similar to those of rats injected with saline alone 
over the entire 3 days after injection, with the exception of a tendency for body 
temperature to be slightly elevated during the lights on period on day 1 (P < 0.05, SNK).  
Fig. 2B shows that the presence of the IL-6AS on its own in the circulation had no effect 
on the circadian rhythm of body temperature of rats. 
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Fig. 3A shows that rats injected with LPS and i.c.v. with the caspase-1 inhibitor had 
significantly lower body temperatures compared to rats injected with LPS alone during 
the expected peak of the fever after injections (P < 0.01, SNK).  Pre-treating rats i.c.v. 
with a caspase-1 inhibitor before LPS did not completely abolish the LPS-induced fever, 
because the body temperatures of rats injected with LPS + caspase-1 inhibitor were still 
significantly elevated compared to the body temperatures of rats injected with saline 
alone during the entire first day after injection (P < 0.05, SNK).  Fig. 3B shows that the 
presence of the caspase-1 inhibitor on its own within the brain had no effect on the 
circadian rhythm of body temperature of rats. 
 
Voluntary wheel-running 
On average, rats ran between 1 and 4 km per day during the 3 days before the 
experimental interventions.  Fig. 4 shows that injection of LPS decreased running activity 
which was most reduced (by 98.1 ± 2.4 %) during day 1 after the LPS injection.  The 
suppression of running activity continued for at least 3 days, because rats injected with 
LPS remained less active on day 3 after the injection when compared to before they 
received LPS (t = 3.3, P < 0.05).  Rats injected with saline alone also decreased their 
running distance significantly on day 1 after injection, but only to the extent of 20.1 ± 
13.2 %, which was significantly less than the decrease in running activity observed in rats 
injected with LPS alone (one-way ANOVA, F(3,26) = 76.5, P < 0.0001).  From day 2 
onwards rats injected with saline ran similar distances to those before the injections.   
Figs. 4A and 4B show that pre-treating rats i.p. with IL-6AS or i.c.v. with a caspase-1 
inhibitor significantly attenuated the LPS-induced suppression of running activity on day 
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1 after the injections (P < 0.05, SNK).  Furthermore, reducing the biological activity of 
IL-6 in the circulation appeared to resolve the LPS-induced suppression of running 
activity faster, because from day 2 onwards rats injected with LPS + IL-6AS were 
running similar distances to their pre-injection values (t = 0.4, P > 0.05) and to rats 
injected with saline alone (P > 0.05, SNK).  The LPS-induced suppression of running 
activity also appeared to be resolved faster in rats injected i.c.v. with the caspase-1 
inhibitor, but only from day 3 onwards (t = 2.1, p > 0.05).  The presence of the IL-6AS on 
its own in the circulation or the caspase-1 inhibitor on its own within the brain had no 
effect on running activity of the rats. 
   
Food intake and body mass 
On average, the daily food intake of the rats was between 7 and 10 g of food per 100 g of 
body mass during the 3 days before the experimental interventions.  Figs. 5 and 6 show 
that the injection of LPS decreased food intake and body mass which was most reduced 
during day 1 after the LPS injection.  Following the initial decrease in food intake rats 
gradually began to eat more food and regain the body mass lost such that by the end of 
day 3 their body mass was similar to that before the injections (t = 1.3, P > 0.05).    
 
Figs. 5 and 6 show that pre-treating rats i.p. with IL-6AS or i.c.v. with the caspase-1 
inhibitor significantly attenuated the LPS-induced anorexia (one-way ANOVA, F(3,26) = 
42.2, P < 0.0001) and the LPS-induced decrease in body mass (one-way ANOVA, F(3,26) 
= 48.7, P < 0.001) on day 1 after the injections.  Furthermore, the presence of IL-6 
antibodies in the circulation or the caspase-1 inhibitor within the brain appeared to 
 98 
resolve the LPS-induced anorexia faster, because from day 2 onwards rats injected with 
LPS + IL-6AS (t = 0.6, P > 0.05) or LPS + caspase-1 inhibitor (t = 0.9, P > 0.05) were 
consuming similar amounts of food to their pre-injection values and to rats injected with 
saline alone (P > 0.05, SNK).  In line with the increased food intake the LPS-induced 
stunting of growth also resolved faster, because rats injected with LPS + IL-6AS (t = 2.2, 
P > 0.05) or LPS + caspase-1 inhibitor (t = 3.6, P < 0.01) had regained the body mass lost 
on day 1 after injections by the end of day 2, and continued to gain weight similarly 
compared to rats injected with saline alone (P > 0.05, SNK).  The presence of the IL-6AS 
on its own in the circulation or the caspase-1 inhibitor on its own within the brain had no 
effect on food intake and growth of the rats. 
 
3.2 Experiment 2: Circulating cytokine responses 
In this experiment circulating levels of bioactive IL-6 and concentrations of IL-1β were 
measured in the plasma 5 h after rats were treated according to the triple-injection 
protocol (i.c.v. and i.p. injections followed 2 hours later with an s.c. injection) described 
in the methods section.  The different experimental conditions will be identified in the 
results section below as they were described for experiment 1 on page 18. 
 
Levels of bioactive IL-6 in plasma 
Fig. 7 shows that rats injected with LPS s.c. had a significant elevation in the biological 
activity of IL-6 in plasma compared to rats injected with saline alone (one-way ANOVA, 
F(3,31) = 119.0 , P < 0.0001).  Pre-treating rats i.p. with IL-6AS significantly attenuated 
the LPS-induced increase in biological activity of IL-6 in the plasma (P < 0.001, SNK).  
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However, it did not completely abolish the LPS-induced increase in plasma IL-6, because 
rats injected with LPS + IL-6AS had greater levels of plasma IL-6 than rats injected with 
saline alone (P < 0.001, SNK).  Pre-treating rats i.c.v. with the caspase-1 inhibitor had no 
significant effect on the biological activity of IL-6 in the plasma (P > 0.05, SNK). 
 
Concentration of IL-1β in plasma 
Fig. 8 shows that rats injected with LPS s.c. had a significant increase in plasma IL-1β 
concentration compared to rats injected with saline alone (one-way ANOVA, F(2,24) = 5.3 
, P < 0.05).  Pre-treating rats i.c.v. with the caspase-1 inhibitor had no effect on the LPS-
induced increase of IL-1β in plasma (P > 0.05, SNK). 
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4. Discussion 
 
We have shown that subcutaneous administration of the pyrogenic moiety of the Gram-
negative bacterial LPS (250 µg/kg), induces fever, lethargy and anorexia in rats.  The 
fever however, which resolved within 2 days (Fig. 1), is outlasted by both the period of 
lethargy and anorexia (Fig. 4 and 5 respectively).  In line with the LPS-induced anorexia 
continuing for at least 3 days, the growth of the rats also was significantly stunted (Fig. 
6).  Our study highlights several important findings regarding the role of cytokines 
released in the periphery and the brain in mediating the induction and duration of 
anorexia and lethargy induced in rats following subcutaneous administration of LPS.  
First, we have shown that endogenous antagonism of peripherally-released IL-6 or IL-1β 
in the brain significantly attenuated both the magnitude and the duration of anorexia 
induced by LPS administration (Figs. 5 and 6).  We further showed that endogenous 
antagonism of peripherally-released IL-6 or IL-1β in the brain significantly reduced 
primarily the duration of lethargy induced by LPS administration (Figs. 4).  Thus, we 
have identified that both peripherally-released IL-6 and IL-1β in the brain appear to be 
important mediators involved in the induction and maintenance of LPS-induced sickness 
behaviors.  Moreover, we also identified that the roles of these two cytokines in the 
anorexia and lethargy induced by LPS is however, different from the roles they appear to 
have in inducing fever irrespective of the degree to which each was antagonized or 
inhibited; fever as a result of systemic administration of LPS is completely abolished in 
rats pre-treated i.p. with IL-6AS (Fig. 2), while it is only partially attenuated in rats pre-
treated i.c.v. with a caspase-1 inhibitor (Fig. 3).   
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Our finding that reducing the biological activity of IL-6 in the circulation completely 
abolishes fever induced by LPS administration supports the consistent observations made 
within our own laboratory and in others, that while other cytokines may be involved, IL-6 
appears to be the primary endogenous pyrogen mediating the fever response [10, 11, 16, 
26].  We also have confirmed our previous finding that peripherally released IL-6 appears 
to contribute significantly to the mediation of LPS-induced anorexia [16].  The 
involvement of peripherally released IL-6 in mediating the anorexia induced by infectious 
agents has also been suggested previously following the finding that the decrease in food 
consumption observed in humans administered endotoxin is positively correlated with the 
secretion of IL-6 [44].  In the hands of others using a different experimental approach to 
investigate the involvement of IL-6 in sickness behavior, that being congenic IL-6 
knockout mice which are deficient in IL-6 production, it was demonstrated, as in our 
study, that the absence of IL-6 also attenuates the loss of body mass induced by LPS 
administration [4].  The absence of IL-6 therefore appears to enable rats and mice to 
resist the anorexia and accompanying loss of body mass induced by systemic and local 
administration of LPS.  
 
Our results showing that treating rats with serum containing IL-6 antibodies enables them 
to recover faster from the suppressive effects of LPS on voluntary activity, demonstrates 
that peripherally-released IL-6 is involved in mediating the duration of fatigue and 
lethargy induced in rats following LPS administration.  In support of the hypothesis that 
IL-6 drives fatigue experienced by patients during illness are the findings that 
administration of human recombinant IL-6 induces a sensation of fatigue in healthy 
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humans at rest [52] and fatigue in patients with cancer is positively correlated with 
circulating levels of IL-6 [47].  Moreover, in an intervention in patients similar to ours 
experimentally in rats, in which a group of patients with multicentric Castleman disease, 
a disease characterized by a dysregulated overproduction of IL-6, were treated with IL-6 
antibodies, the previously debilitating fatigue reported by these patients disappeared [36, 
37].  Fatigue experienced by patients during illness results in a decrease in daily activity, 
probably not unlike the decrease in voluntary activity in the rats of our study.   
 
Although we have identified that IL-6 released into the bloodstream from peripherally 
located immune cells appears to be involved in mediating lethargy, anorexia and fever 
during infection, our finding that reducing the biological activity of IL-6 in the circulation 
at most attenuates the behavioral responses to LPS but does not completely abolish them, 
highlights differences in the cytokine mechanisms mediating LPS-induced fever and 
LPS-induced anorexia and lethargy.  There are two possible explanations for the 
differences we observed in the initial degree of attenuation, complete for the fever 
response versus partial for the anorexia and lethargy.  Firstly, although we reduced the 
level of bioactive IL-6 in the circulation substantially (~ 80 %, see Fig 7) we did not 
completely neutralize it and there may have been sufficient IL-6 still to induce the 
anorexia and lethargy we observed on the first day after injection.  Secondly, a more 
likely possibility is that mediators in addition to IL-6, possibly other cytokines, are also 
involved in regulating the LPS-induced anorexia and lethargy.  Antagonizing the 
biological action of IL-1β in the brain by injecting a caspase-1 inhibitor, which prevents 
the cleavage of pro-IL-1β to biologically active IL-1β, we were able to identify that IL-1β 
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in the brain also is likely to be involved in mediating the anorexia and lethargy induced 
by LPS administration. 
 
Our results showing that treating rats with a capsase-1 inhibitor enables them to recover 
faster from the suppressive effects of LPS on voluntary activity demonstrate a possible 
role for IL-1β within the brain in mediating the duration of fatigue and lethargy induced 
by LPS.  In support of this finding is a previously reported observation from our 
laboratory that centrally administered IL-1β induces a dose-dependent decrease in 
voluntary activity [17].  Moreover, there is some preliminary evidence that supports the 
involvement of IL-1β in mediating the fatigue experienced by patients during illness, 
because administering IL-1ra to patients with rheumatoid arthritis induces rapid and 
persistent improvements in fatigue scores [38].  Not only did treating rats centrally with a 
caspase-1 inhibitor enable them to recover faster from the suppressive effects of LPS on 
voluntary activity, but so too on food intake and growth.  Moreover, i.c.v. administration 
of the caspase-1 inhibitor attenuated the LPS-induced fever also.   
 
Using a different agent, IL-1ra, to antagonize the biological action of IL-1β in the brain, 
others also have investigated the involvement of endogenous brain IL-1β in mediating 
fever and sickness behavior induced by i.p. administration of LPS [3, 8, 25, 30, 33, 34].  
Although these studies have consistently shown that inhibition of endogenous brain IL-1β 
attenuates LPS-induced fever, unlike the findings in our study, they mostly have failed to 
show that it also can attenuate LPS-induced sickness behaviors.  The failure of i.c.v 
administration of IL-1ra to attenuate LPS-induced sickness behaviors may be related to 
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IL-1ra being active for a significantly shorter period of time (2 -4 h) [3] in comparison to 
the prolonged duration (8 – 24 h) for which endogenous IL-1β is elevated in the brain [2].  
The actions of brain-intrinsic cytokines, produced after the production of cytokines in the 
periphery, are generally believed to be more important in mediating sickness behaviors 
than fever during infection/inflammation [12].  Thus while the short duration of action of 
IL-1ra may be sufficient to inhibit the action of endogenous brain IL-1β in mediating 
fever, it may not be sufficient to significantly influence the prolonged sickness behaviors.  
The caspase-1 inhibitor used in our study is active for at least 24 h [41], therefore the 
longer period of brain IL-1β inhibition likely to be achieved with the caspase-1 inhibitor 
may have accounted for the reduction in the duration of the sickness behavior responses 
noted in our study.   
 
While it has been established that administration of a caspase-1 inhibitor effectively 
reduces IL-1β activity in vivo following systemic administration of LPS [2], we did not 
measure the concentration of IL-1β in the brain and therefore cannot confirm the extent to 
which i.c.v. administration of the caspase-1 inhibitor inhibited the synthesis of IL-1β in 
the brain.  It is therefore possible that if IL-1β was not completely inhibited by the dose 
of the caspase-1 inhibitor we injected, the contribution of endogenous brain IL-1β to 
mediating the anorexia and lethargy induced by s.c. administration of LPS we noted may 
be of a greater magnitude.  It also is possible that the responses we noted, particularly for 
food intake and body mass, following i.c.v. administration of the caspase-1 inhibitor may 
not be entirely specific to the action of IL-1β, but may also be related to reducing the 
action of other pro-inflammatory cytokines implicated as putative mediators of appetite 
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such as IL-18 [57], because the enzyme caspase-1 is not only involved in the processing 
of IL-1β, but is also involved in the processing of IL-18 and IL-33 [14].  Irrespective of 
whether the synthesis of other cytokines were affected within the brain, the established 
effectiveness of the caspase-1 inhibitor at reducing endogenous IL-1β [2], indicates that a 
significant portion of the responses we noted are related to inhibiting the action of IL-1β. 
 
How endogenous brain IL-1β influences the brain sites controlling appetite, activity and 
temperature during a systemic infection remains unclear however.  Studies investigating 
the interaction of IL-1β with hypothalamic mechanisms involved in the regulation of 
feeding [40] and temperature [7, 49] provide evidence for the possibility of both direct 
(via neuronal mechanisms) and indirect (via modulation of brain chemistry) actions.  In 
terms of the indirect actions, IL-1β can modulate hypothalamic chemistry by generating 
mediators such as prostaglandins, and by interacting with various neurotransmitters (e.g. 
serotonin) and peptides (e.g. neuropeptide Y) within the brain [9, 28].  The generation of 
proximal mediators such as prostaglandins and serotonin within the brain and the 
endothelial cells lining the vasculature throughout the brain, are also possible 
mechanisms by which IL-6 released into the bloodstream from peripherally located 
immune cells mediates fever and sickness behaviors during a systemic infection [15, 21, 
46, 50].  In addition to inducing these proximal mediators it also is likely that 
peripherally-released IL-6 could be mediating lethargy, anorexia and fever via the 
induction of IL-1β in the brain, as others have reported that in the absence of IL-6 i.p. 
administration of LPS failed to induce IL-1β in the brain [51].   
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Although the results from our study clearly identify IL-6 as an important humoral 
mediator by which inflammatory challenges in the periphery can communicate with the 
brain to induce lethargy, anorexia and fever, they may not hold true under some 
experimental conditions.  For example, injecting a lower does of LPS s.c. than the dose 
we used in our study (250 µg/kg) may induce a more localized response with 
significantly lower concentrations of IL-6 appearing in the blood.  Under these conditions 
other signaling pathways, possibly afferent neural pathways from the skin to the central 
nervous system, are likely to be more important than humoral pathways in mediating 
fever and sickness behavior [45].  As activation of neural pathways during a peripheral 
immune challenge has been related to increased expression of IL-1β mRNA in the brain 
of mice [29] it is likely that brain IL-1β may remain an important endogenous mediator 
of fever and sickness behaviors induced during localized infection/inflammation. 
 
In conclusion, we have shown that pre-treating rats with either antibodies to IL-6 i.p. or a 
caspase-1 inhibitor i.c.v. significantly enhanced the resolution of anorexia and lethargy 
by at least two days, but it did not completely prevent these sickness behaviors from 
occurring.  Our inability to abolish the anorexia and lethargy with antagonism of 
individual cytokines appears to indicate the complexity of the cytokine involvement in 
mediating these two sickness behaviors during a localized Gram-negative bacterial 
infection.  Using similar experimental tools, others [54] have also noted this trend of 
multiple cytokine involvement in mediating sickness behaviors during a systemic Gram-
negative bacterial infection.  Therefore while individual cytokines, such as IL-6 and IL-
1β, are possible targets for therapies aimed at alleviating the debilitating consequences of 
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anorexia and lethargy in patients with prolonged bacterial infections, it appears that to 
abolish the presence of sickness behaviors multiple cytokines may need to be targeted.  
Although inhibiting the action of cytokines may provide some relief for patients 
experiencing sickness symptoms, this action could possibly compromise the ability of the 
host to fight infection in the situation of a live, replicating pathogen, as pro-inflammatory 
cytokines also perform important immune functions which facilitate pathogen 
elimination.  Selectively inhibiting the downstream mediators by which cytokines induce 
sickness behaviors may prove to be a better tool therapeutically, as that could preserve 
the actions of pro-inflammatory mediators required for pathogen elimination yet improve 
the anorexia and fatigue in the patient.   
 
Acknowledgements 
 
We are grateful to the Lennox Nqobo and Kwandakwethu Ndaba for assistance with 
experimental procedures, Kennedy Erlwanger, Leith Meyer and staff of the Central 
Animal Service for assistance with surgery and care of the animals, Lisa Loram and 
Margaret Badenhorst for assistance with the ELISA, Jolanta Murgott for assistance with 
the B9 bioassay, NIBSC for providing the IL-6 antiserum and Charles Dinarello for 
guidance on appropriate agents to use for IL-1β antagonism.  This work was supported by 
the Medical Research Council of South Africa and National Research Foundation of 
South Africa. 
 
 
 108 
References 
 
[1]    Aarden LA, De Groot ER, Schaap OL, Lansdorp PM. Production of hybridoma    
     growth factor by human monocytes. Eur J Immunol 1987;17:1411-16. 
[2]    Bilbo SD, Biedenkapp JC, Der-Avakian A, Watkins LR, Rudy JW, Maier SF.     
         Neonatal infection-induced memory impairment after lipopolysaccharide in      
      adulthood is prevented via caspase-1 inhibition. J Neurosci 2005;25:8000-09. 
[3]    Bluthé RM, Dantzer R, Kelley KW. Effects of interleukin-1 receptor antagonist on   
         the behavioral effects of lipopolysaccharide in rat. Brain Res 1992;573:318-20. 
[4]    Bluthé RM, Michaud B, Poli V, Dantzer R. Role of IL-6 in cytokine-induced  
      sickness behavior: a study with IL-6 deficient mice. Physiol Behav 2000;70:367-73. 
[5]    Bluthé RM, Pawlowski M, Suarez S, Parnet P, Pittman Q, Kelley KW, et al.  
      Synergy between tumor necrosis factor alpha and interleukin-1 in the induction of     
      sickness behavior in mice. Psychoneuroendocrinology 1994;19:197-207. 
[6]    Burgess W, Gheusi G, Yao J, Johnson RW, Dantzer R, Kelley KW. Interleukin- 
         1beta-converting enzyme-deficient mice resist central but not systemic endotoxin- 
         induced anorexia. Am J Physiol Regul Integr Comp Physiol 1998;274:R1829-R33. 
[7]    Cao C, Matsumura K, Shirakawa N, Maeda M, Jikihara I, Kobayashi S, et al.  
         Pyrogenic cytokines injected into the rat cerebral ventricle induce cyclooxygenase-2    
         in brain endothelial cells and also upregulate their receptors. Eur J Neurosci      
         2001;13:1781-90. 
[8]    Cartmell T, Luheshi GN, Rothwell NJ. Brain sites of action of endogenous    
         interleukin-1 in the febrile response to localized inflammation in the rat. J Physiol  
 109 
         1999;518:585-94. 
[9]    Cartmell T, Mitchell D. The molecular basis of fever. In: Steckler T, Kalin NH,  
      Reul, JMHM, eds. Handbook of Stress and the Brain Part 2 Stress: Integrative and  
      Clinical Aspects. Amsterdam, 2005:p193-227. 
[10]  Cartmell T, Poole S, Turnbull AV, Rothwell NJ, Luheshi GN. Circulating  
         interleukin-6 mediates the febrile response to localised inflammation in rats. J   
         Physiol. 2000;526:653-61. 
[11]  Chai Z, Gatti S, Toniatti C, Poli V, Bartfai T. Interleukin (IL)-6 gene expression  
         in the central nervous system is necessary for fever response to lipopolysaccharide    
         or IL-1 beta: a study on IL-6-deficient mice. J Exp Med 1996;183:311-16. 
[12]  Dantzer R. Cytokine-induced sickness behavior: where do we stand? Brain Behav  
         Immun 2001;15:7-24. 
[13]  Dinarello CA. Cytokines as endogenous pyrogens. J Infect Dis 1999;179:S294- 
      S304. 
[14]  Dinarello CA. An IL-1 family member requires caspase-1 processing and signals  
         through the ST2 receptor. Immunity 2005;23:461-62. 
[15]  Dunn AJ. Endotoxin-induced activation of cerebral catecholamine and serotonin  
         metabolism: comparison with interleukin-1. J Pharmacol Exp Ther 1992;261:964- 
       69. 
[16]  Harden LM, du Plessis I, Poole S, Laburn HP. Interleukin-6 and leptin mediate  
         lipopolysaccharide-induced fever and sickness behavior. Physiol Behav  
       2006;89:14-55. 
[17]  Harden LM, du Plessis I, Poole S, Laburn HP. Interleukin (IL)-6 and IL-1 beta act  
 110 
         synergistically within the brain to induce sickness behavior and fever in rats. Brain  
         Behav Immun 2008;22:838-49. 
[18]  Hart BL. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev  
         1988;12:123-37. 
[19]  Hewlett S, Cockshott Z, Byron M, Kitchen K, Tipler S, Pope D, et al. Patients'  
         perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable,  
      ignored. Arthritis Rheum 2005;53:697-702. 
[20]  Holt I, Cooper RG, Hopkins SJ. Relationships between local inflammation,  
         interleukin-6 concentration and the acute phase protein response in arthritis patients.  
         Eur J Clin Invest 1991;21:479-84. 
[21]  Johnson PM, Vogt SK, Burney MW, Muglia LJ. COX-2 inhibition attenuates  
         anorexia during systemic inflammation without impairing cytokine production. Am  
      J Physiol Endocrinol Metab 2002;282:E650-E56. 
[22]  Kelley KW, Bluthé RM, Dantzer R, Zhou JH, Shen WH, Johnson RW, et al.  
         Cytokine-induced sickness behavior. Brain Behav Immun 2003;17:S112-S18. 
[23]  Kent S, Bluthé RM, Kelley KW, Dantzer R. Sickness behavior as a new target for  
         drug development. Trends Pharmacol Sci 1992;13:24-8. 
[24]  Kent S, Bluthé RM, Kelley KW, Dantzer R. Sickness behavior as a new target for  
         drug development. Trends Pharmacol Sci 1992;13:24-28. 
[25]  Kent S, Kelley KW, Dantzer R. Effects of lipopolysaccharide on food-motivated  
         behavior in the rat are not blocked by an interleukin-1 receptor antagonist. Neurosci  
         Lett 1992;145:83-86. 
[26]  Kozak W, Kluger MJ, Soszynski D, Conn CA, Rudolph K, Leon LR, et al. IL-6 and  
 111 
         IL-1 beta in fever. Studies using cytokine-deficient (knockout) mice. Ann N Y  
         Acad Sci 1998;856:33-47. 
[27]  Kozak W, Zheng H, Conn CA, Soszynski D, van der Ploeg LH, Kluger MJ.  
         Thermal and behavioral effects of lipopolysaccharide and influenza in interleukin-1  
         beta-deficient mice. Am J Physiol Regul Integr Comp Physiol 1995;269:R969-R77. 
[28]  Langhans W. Signals generating anorexia during acute illness. Proc Nutr Soc   
         2007;66:321-30. 
[29]  Layé S, Bluthé RM, Kent S, Combe C, Medina C, Parnet P, et al. Subdiaphragmatic   
         vagotomy blocks induction of IL-1 beta mRNA in mice brain in response to  
         peripheral LPS. Am J Physiol Regul Integr Comp Physiol 1995;268:R1327-R31. 
[30]  Layé S, Gheusi G, Cremona S, Combe C, Kelley K, Dantzer R, et al. Endogenous  
         brain IL-1 mediates LPS-induced anorexia and hypothalamic cytokine expression.  
        Am J Physiol Regul Integr Comp Physiol 2000;279:R93-R8. 
[31]  Leon LR, Conn CA, Glaccum M, Kluger MJ. IL-1 type I receptor mediates acute  
         phase response to turpentine, but not lipopolysaccharide, in mice. Am J Physiol  
         Regul Integr Comp Physiol 1996;271:R1668-R75. 
[32]  Leon LR, Kozak W, Peschon J, Kluger MJ. Exacerbated febrile responses to LPS,  
         but not turpentine, in TNF double receptor-knockout mice. Am J Physiol Regul  
         Integr Comp Physiol 1997;272:R563-R69. 
[33]  Luheshi G, Miller AJ, Brouwer S, Dascombe MJ, Rothwell NJ, Hopkins SJ.  
         Interleukin-1 receptor antagonist inhibits endotoxin fever and systemic interleukin-6  
         induction in the rat. Am J Physiol Regul Integr Comp Physiol 1996;270:E91-E5. 
[34]  Miller AJ, Hopkins SJ, Luheshi GN. Sites of action of IL-1 in the development of  
 112 
         fever and cytokine responses to tissue inflammation in the rat. Br J Pharmacol  
         1997;120:1274-79. 
[35]  Netea MG, Kullberg BJ, Vonk AG, Verschueren I, Joosten LA, van der Meer JW.  
         Increased voluntary exercise in mice deficient for tumour necrosis factor-alpha and  
         lymphotoxin-alpha. Eur J Clin Invest 2007;37:737-41. 
[36]  Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al.  
         Humanized anti-interleukin-6 receptor antibody treatment of multicentric  
      Castleman disease. Blood 2005;106:2627-32. 
[37]  Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, et al.  
         Improvement in Castleman's disease by humanized anti-interleukin-6 receptor  
         antibody therapy. Blood 2000;95:56-61. 
[38]  Omdal R, Gunnarsson R. The effect of interleukin-1 blockade on fatigue in  
         rheumatoid arthritis--a pilot study. Rheumatol Int 2005;25:481-4. 
[39]  Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 4th ed. San  
         Diego: Academic Press, 1998. 
[40]  Plata-Salaman CR. Cytokines and Feeding. News Physiol Sci 1998;13:298-304. 
[41]  Rabuffetti M, Sciorati C, Tarozzo G, Clementi E, Manfredi AA, Beltramo M.  
         Inhibition of caspase-1-like activity by Ac-Tyr-Val-Ala-Asp-chloromethyl ketone  
         induces long-lasting neuroprotection in cerebral ischemia through apoptosis  
      reduction and decrease of proinflammatory cytokines. J Neurosci 2000;20:4398- 
      404. 
[42]  Rees GS, Ball C, Ward HL, Gee CK, Tarrant G, Mistry Y, et al. Rat interleukin 6:  
         expression in recombinant Escherichia coli, purification and development of a novel  
 113 
         ELISA. Cytokine 1999;11:95-103. 
[43]  Rees GS, Gee CK, Ward HL, Ball C, Tarrant GM, Poole S, et al. Rat tumour  
      necrosis factor-alpha: expression in recombinant Pichia pastoris, purification,  
      characterization and development of a novel ELISA. Eur Cytokine Netw  
      1999;10:383-92. 
[44]  Reichenberg A, Kraus T, Haack M, Schuld A, Pollmacher T, Yirmiya R.  
      Endotoxin-induced changes in food consumption in healthy volunteers are  
      associated with TNF-alpha and IL-6 secretion. Psychoneuroendocrinology  
      2002;27:945-56. 
[45]  Ross G, Roth J, Storr B, Voigt K, Zeisberger E. Afferent nerves are involved in the   
         febrile response to injection of LPS into artificial subcutaneous chambers in guinea 
         pigs. Physiol Behav 2000;71:305-13. 
[46]  Rummel C, Sachot C, Poole S, Luheshi GN. Circulating interleukin-6 induces fever   
         through a STAT3-linked activation of COX-2 in the brain. Am J Physiol Regul  
      Integr Comp Physiol 2006;291:R1316-R26. 
[47]  Schubert C, Hong S, Natarajan L, Mills PJ, Dimsdale JE. The association between   
         fatigue and inflammatory marker levels in cancer patients: a quantitative review.   
         Brain Behav Immun 2007;21:413-27. 
[48]  Sheng WS, Hu S, Lamkin A, Peterson PK, Chao CC. Susceptibility to   
         immunologically mediated fatigue in C57BL/6 versus Balb/c mice. Clin Immunol  
         Immunopathol 1996;81:161-67. 
[49]  Shibata M, Blatteis CM. Differential effects of cytokines on thermosensitive  
      neurons in guinea pig preoptic area slices. Am J Physiol Regul Integr Comp Physiol   
 114 
         1991;261:R1096-R103. 
[50]  Soares DD, Coimbra CC, Marubayashi U. Tryptophan-induced central fatigue in  
         exercising rats is related to serotonin content in preoptic area. Neurosci Lett  
         2007;415:274-78. 
[51]  Sparkman NL, Buchanan JB, Heyen JR, Chen J, Beverly JL, Johnson RW.  
         Interleukin-6 facilitates lipopolysaccharide-induced disruption in working memory  
         and expression of other proinflammatory cytokines in hippocampal neuronal cell  
         layers. J Neurosci 2006;26:10709-16. 
[52]  Spath-Schwalbe E, Hansen K, Schmidt F, Schrezenmeier H, Marshall L, Burger K,  
      et al. Acute effects of recombinant human interleukin-6 on endocrine and central  
      nervous sleep functions in healthy men. J Clin Endocrinol Metab 1998;83:1573-9. 
[53]  Strassmann G, Fong M, Windsor S, Neta R. The role of interleukin-6 in  
         lipopolysaccharide-induced weight loss, hypoglycemia and fibrinogen production,  
      in vivo. Cytokine 1993;5:285-90. 
[54]  Swiergiel AH, Dunn AJ. The roles of IL-1, IL-6, and TNFalpha in the feeding  
         responses to endotoxin and influenza virus infection in mice. Brain Behav Immun  
         1999;13:252-65. 
[55]  Tisdale MJ. Molecular pathways leading to cancer cachexia. Physiology (Bethesda)  
         2005;20:340-8. 
[56]  Töllner B, Roth J, Störr B, Martin D, Voigt K, Zeisberger E. The role of tumor  
         necrosis factor (TNF) in the febrile and metabolic responses of rats to  
      intraperitoneal injection of a high dose of lipopolysaccharide. Pflugers Arch  
      2000;440:925-32. 
 115 
[57]  Zorrilla EP, Sanchez-Alavez M, Sugama S, Brennan M, Fernandez R, Bartfai T, et  
      al. Interleukin-18 controls energy homeostasis by suppressing appetite and feed  
      efficiency. Proc Natl Acad Sci U S A 2007;104:11097-102. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 116 
 
Legends 
 
Figure 1.  Circadian rhythms of body temperature over approximately 3 days (separated 
by vertical ----) after rats were injected i.p. with pre-immune serum (PIS 1.5 ml) and i.c.v. 
with the vehicle 2 h before receiving the s.c. injections of LPS (250 µg/kg) or saline 30 
min before lights off on the first day.     *   Indicates the period during which the body 
temperature of rats injected with LPS was significantly greater than the body temperature 
of rats injected with saline (P < 0.01, SNK).  The results are represented as mean ± SD.  
The first arrow indicates the time of injection for the i.p. and i.c.v. injections and the 
second arrow indicates the time of injection for the s.c. injections.  The black bars 
indicate lights off (10:30 - 22:30 clock time). 
 
Figure 2.  Circadian rhythms of body temperature over approximately 3 days after rats 
were injected with: (A) IL-6AS (1.5 ml) or PIS (1.5 ml) i.p. and the vehicle for the 
caspase-1 injection i.c.v. 2 h before receiving s.c. injections of LPS (250 µg/kg); (B) IL-
6AS or PIS and the vehicle for the caspase-1 injection i.c.v. 2 h before receiving s.c. 
injections of saline.  In A the effects of saline + PIS + veh also is shown and is the same 
as the results shown in B.    *   Indicates the period during which the body temperature of 
rats injected with LPS + PIS + veh was significantly greater than the body temperature of 
rats injected with LPS + IL-6AS + veh (P < 0.01, SNK).    #   Indicates the period during 
which the body temperature of rats injected with LPS + IL-6AS + veh was significantly 
greater than the body temperature of rats injected with saline + PIS + veh (P < 0.05, 
SNK).  The results are represented as mean ± SD.  The first arrow indicates the time of 
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injection for the i.p. and i.c.v. injections and the second arrow indicates the time of 
injection for the s.c. injections.  The black bars indicate lights off (10:30 - 22:30 clock 
time). 
 
Figure 3.  Circadian rhythms of body temperature over approximately 3 days after rats 
were injected with: (A) PIS (1.5 ml) i.p. and the caspase-1 inhibitor (300 ng/5µl) or its 
vehicle i.c.v. 2 h before receiving s.c. injections of LPS (250 µg/kg); (B) PIS i.p. and the 
caspase-1 inhibitor (300 ng/5µl) or its vehicle i.c.v. 2 h before receiving s.c. injections of 
saline.  In A the effects of saline + PIS + veh also is shown and is the same as the results 
shown in B.     *   Indicates the period during which the body temperature of rats injected 
with LPS + PIS + veh was significantly greater than the body temperature of rats injected 
with LPS + PIS + casp-inh (P < 0.01, SNK).    #   Indicates the period during which the 
body temperature of rats injected with LPS + PIS + casp-inh was significantly greater 
than the body temperature of rats injected with saline + PIS + veh (P < 0.05, SNK).  The 
results are represented as mean ± SD.  The first arrow indicates the time of injection for 
the i.p. and i.c.v. injections and the second arrow indicates the time of injection for the 
s.c. injections.  The black bars indicate lights off (10:30 - 22:30 clock time). 
 
Figure 4.  Percentage change from pre-injection days, in daily wheel-running distance 
determined from the number of wheel turns measured during 3 days after rats were 
injected with: (A) PIS (1.5 ml) or IL-6AS (1.5 ml) i.p. and the vehicle for the caspase-1 
injection i.c.v. 2 h before receiving a s.c. injection of LPS (250 µg/kg) or saline; (B) PIS 
i.p. and the caspase-1 inhibitor (300 ng/5 µl) or its vehicle i.c.v. 2 h before receiving a s.c. 
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injection of LPS or saline.   *   Indicates percentage change in running distances are 
significantly different to pre-injection days’ running distances (P < 0.05).  # Indicates 
significant differences between rats injected with LPS + PIS + veh versus all other 
experimental groups (P < 0.05, SNK).  + Indicates significant differences between rats 
injected with saline + PIS + veh versus rats injected with LPS + IL-6AS + veh and LPS + 
PIS + casp-inh on the first day (P < 0.001, SNK).  There were no significant differences 
between rats injected with saline + PIS + veh, saline + IL-6AS + veh and saline + PIS + 
casp-inh.  The results are represented as mean ± SD.   
 
Figure 5.  Percentage change from pre-injection days, in daily food intake calculated as 
grams of food consumed in 24 h per 100 gram of rat body mass, during 3 days after rats 
were injected with: (A) PIS (1.5 ml) or IL-6AS (1.5 ml) i.p. and the vehicle for the 
caspase-1 injection i.c.v. 2 h before receiving a s.c. injection of LPS (250 µg/kg) or 
saline; (B) PIS i.p. and the caspase-1 inhibitor (300 ng/5 µl) or its vehicle i.c.v. and 2 h 
before receiving a s.c. injection of LPS or saline.    *   Indicates percentage change in food 
intake is significantly different to pre-injection food intake (P < 0.05).  # Indicates 
significant differences between rats injected with LPS + PIS + veh versus all other 
experimental groups (P < 0.05, SNK).  + Indicates significant differences between rats 
injected with saline + PIS + veh versus rats injected with LPS + IL-6AS + veh and LPS + 
PIS + casp-inh on the first day (P < 0.05, SNK).  There were no significant differences 
between rats injected with saline + PIS + veh, saline + IL-6AS + veh and saline + PIS + 
casp-inh.  The results are represented as mean ± SD.   
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Figure 6.  Change in body mass from pre-injection values on each of the 3 days after rats 
were injected with: (A) PIS (1.5 ml) or IL-6AS (1.5 ml) i.p. and the vehicle for the 
caspase-1 injection i.c.v. 2 h before receiving a s.c. injection of LPS (250 µg/kg) or 
saline; (B) PIS i.p. and the caspase-1 inhibitor (300 ng/5 µl) or its vehicle i.c.v. 2 h before 
receiving a s.c. injection of LPS or saline.    *   Indicates a significant change in body mass 
compared to pre-injection values (P < 0.05).  # Indicates significant differences between 
rats injected with LPS + PIS + veh versus all other experimental groups (P < 0.05, SNK).  
+
 Indicates significant differences between rats injected with saline + PIS + veh versus 
rats injected with LPS + IL-6AS + veh and LPS + PIS + casp-inh on the first day (P < 
0.001, SNK).  There were no significant differences between rats injected with saline + 
PIS + veh, saline + IL-6AS + veh and saline + PIS + casp-inh.  The results are 
represented as mean ± SD.   
 
Figure 7.  Plasma concentrations of bioactive IL-6 for rats injected i.p. with PIS (1.5 ml) 
or IL-6AS (1.5 ml) and i.c.v. with a caspase-1 inhibitor (300 ng/5 µl) or its vehicle 2 h 
before receiving s.c. injections of LPS (250 µg/kg) or saline.  The plasma concentrations 
of bioactive IL-6 were measured 5 h after rats were injected with LPS or saline.  * 
Indicates significant differences between rats injected with LPS + IL-6AS + veh versus 
all other experimental groups (P < 0.001, SNK).  # Indicates significant differences 
between rats injected with saline + PIS + veh versus all other experimental groups (P < 
0.001, SNK).  The detection limit of the assay was 3 IU of IL6 ml-1.  The results are 
represented as mean ± SD.   
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Figure 8.  Plasma concentrations of IL-1β for rats injected with PIS (1.5 ml) i.p. and the 
caspase-1 inhibitor (300 ng/5 µl) or its vehicle 2 h before receiving s.c. injections of LPS 
(250 µg/kg) or saline.  The plasma concentrations of IL-1β were measured 5 h after rats 
were injected with LPS or saline.  * Indicates significant differences between rats injected 
with saline + PIS + veh versus all other experimental groups (P < 0.05, SNK).  The 
results are represented as mean ± SD.  Dashed line indicates level of detection of assay. 
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CHAPTER 5 
 
CONCLUSIONS 
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Peripherally-released cytokines have been strongly implicated as important endogenous 
mediators of the brain-controlled fever mechanism activated following systemic and local 
administration of LPS.  In contrast to the important role established for peripherally-
released cytokines in mediating LPS-induced fever, no clear role has emerged as yet for 
these cytokines as endogenous mediators of anorexia and lethargy, two brain-controlled 
sickness behaviours, also known to be induced following systemic and local 
administration of LPS.  Using endogenous antagonism of the biological action of 
cytokines as far as possible, and highly quantifiable measures of anorexia and lethargy, I 
therefore systematically investigated the contribution of endogenous pyrogenic cytokines 
in mediating anorexia and lethargy induced by local subcutaneous administration of LPS.  
I specifically chose to simulate infection using LPS (extracted from Escherichia coli) as it 
a powerful activator of the innate immune system and pro-inflammatory cytokine release, 
and understanding the physiological mechanism of its biological action has significant 
clinical application, as Gram-negative sepsis in humans is caused by Enterobacteriaceae 
such as Escherichia coli and Klebsiella species (Bochud & Calandra, 2003). The results 
obtained from the studies I undertook are summarized and discussed below in the context 
of the current literature.         
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5.1 The contribution of cytokines released in the periphery and the brain in   
      mediating anorexia and lethargy induced by subcutaneous administration of  
      LPS 
 
To establish a role for molecules, such as cytokines, as endogenous mediators of a given 
biological response it is imperative that inhibition of the biological action or synthesis of 
the molecule at a site that relates to its observed synthesis and action, is shown to inhibit 
or abolish the biological response in question (Kluger, 1991).  Injecting species-specific 
neutralizing antibodies to therefore effect endogenous antagonism, I investigated in 
chapter 2 whether peripherally-released IL-6, IL-1β, TNF-α and leptin, cytokines shown 
to be endogenous mediators of LPS-induced fever, also contribute in mediating two 
specific sickness behaviours, anorexia and lethargy in rats.  I used highly quantifiable and 
sensitive measures, quantity of food consumed and voluntary wheel-running, to assess 
anorexia and lethargy, in the rats.   
   
I found that injecting rats s.c. with LPS (250 µg kg-1) before the night-time active period, 
dramatically affected their activity levels, as most of the rats did not run at all on the 
night after injection.  Food intake was also affected following the LPS injection, but to a 
lesser extent than voluntary activity, with the rats reducing the quantity of food they 
normally consumed by about half (Chapter 2).  Treating rats peripherally with species-
specific IL-6 antiserum significantly attenuated the LPS-induced decrease in food intake 
and voluntary activity.  Thus I have identified that peripherally-released IL-6 plays a role 
in mediating the lethargy and anorexia induced by local administration of LPS.  The idea 
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that IL-6 is involved in mediating LPS-induced sickness behaviours has been mooted 
before by others (Bluthé et al., 2000b) studying the effect of systemic administration of 
LPS on body mass and social behaviour, another behavioural response affected during 
infection.  Bluthé et al., (2000) observed that IL-6 deficient mice (IL-6 -/-) were less 
sensitive than wild-type (IL-6 +/+) mice to the depressing effects of i.p. administration of 
LPS on social behaviour and body mass.  
 
While peripherally-released IL-6 appears unequivocally to be contributing to mediating 
LPS-induced sickness behaviours, it is important to note that the sickness behaviours are 
only attenuated and not abolished when the biological activity of IL-6 is inhibited.  There 
are two likely explanations for why these sickness behaviour responses were only 
attenuated.  Firstly, it is possible that not all peripherally-released IL-6 was neutralized by 
the dose of IL-6 antiserum I administered.  Secondly, additional endogenous mediators, 
possibly other cytokines, could be working in parallel with peripherally-released IL-6 to 
regulate anorexia and lethargy induced by s.c. administration of LPS.  As others 
(Cartmell et al., 2000) have demonstrated complete neutralization of the LPS-induced 
increase in circulating IL-6 in rats using an equivalent dose of IL-6 antiserum to the dose 
I used, the attenuated responses I noted appear to rather reflect the involvement of 
additional mediators.  To determine if these mediators were possibly other cytokines 
released in the periphery following LPS administration I injected rats i.p. with species-
specific antiserum to either TNF-α or IL-1β before administering LPS. 
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Treating rats peripherally with either TNF-α antiserum or IL-1β antiserum had no effect 
on the LPS-induced suppression of voluntary activity and food intake (chapter 2).  Thus I 
identified that peripherally-released IL-1β and TNF-α do not appear to be involved in 
mediating lethargy and anorexia induced by local administration of LPS. Although I do 
not provide in vivo evidence of neutralization of TNF-α and IL-1β in the circulation, it is 
unlikely that my failure to attenuate the LPS-induced anorexia and LPS-induced lethargy 
was due to the neutralization being incomplete, as I determined using an in vitro two-site 
sandwich ELISA that one hundred microlitres of the antiserum could neutralize up to 10, 
000 pg of rat recombinant TNF-α and IL-1β (unpublished observations).  From the results 
presented in later experiments (chapter 4), where I measured the concentration of IL-1β 
in the plasma, it would appear that the dose of IL-1β antiserum I administered (1.5 ml) 
should have been more than sufficient to neutralize the increase in plasma concentrations 
of IL-1β (~ 38 pg ml-1) induced by the dose of LPS I administered (250 µg kg-1).   
 
The increase in plasma concentrations of IL-1β I measured in my study following local 
LPS administration is substantially lower than the increase (~ 350 pg ml-1) measured by 
others, at the same time point, injecting a ten-fold lower dose of LPS (25 µg kg-1) 
systemically (Bilbo et al., 2005).  A similar difference also has been noted in the 
concentration of TNF-α measured in plasma when injecting LPS systemically versus 
locally into an air pouch.  Injecting LPS into an air pouch did not significantly increase 
TNF-α in the plasma, however injecting the same dose of LPS (100 µg kg-1) systemically 
did (peak concentration ~ 1636 pg ml-1) (Miller et al., 1997b).  Injecting LPS s.c. as I did 
may therefore be a more representative model of localized infection, similar to injecting 
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LPS into a pre-formed subcutaneous airpouch.  In this experimental model of localized 
infection only IL-6 is significantly elevated in the circulation, with the increase in TNF-α 
and IL-1β mostly being confined to the local infection site (Miller et al., 1997b).  From 
my findings that injecting rats peripherally with either TNF-α or IL-1β antiserum has no 
effect on the anorexia and lethargy induced by local administration of LPS, I 
hypothesized that if other cytokines are working with peripherally-released IL-6 to induce 
anorexia and lethargy, it is due primarily to their synthesis in the brain and not in the 
periphery.   
 
In chapter 3 I therefore investigated whether specific cytokines likely to fulfil this role, 
such as IL-1β and IL-6, could act within the brain to induce anorexia and lethargy.  I 
found that i.c.v. administration of either species-homologous rat IL-6 or IL-1β before the 
night-time active period decreased voluntary activity in rats in a dose-dependent fashion.  
These findings were the first to show that voluntary exercise, that is wheel-running, is 
suppressed by direct administration into the brain, of IL-6 and IL-1β.  While voluntary 
exercise was significantly reduced by i.c.v. administration of either IL-6 or IL-1β, food 
intake was only decreased by i.c.v. injection of IL-1β at the highest dose I used, but not 
IL-6 at any dose.  Having identified that IL-6 can act endogenously to induce anorexia 
and lethargy my finding that central administration of IL-6 affected voluntary exercise, 
but did not affect food intake was surprising.  Although it is yet to be established how IL-
6 released into the bloodstream from peripherally located immune cells influences the 
brain-mediated response of anorexia and lethargy during a peripheral immune challenge, 
my findings presented in chapter 3 identify that the direct action of IL-6 on the 
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hypothalamic neurones involved in the control of food intake may not be a prerequisite.  
Rather, the induction of anorexia may be more dependent on peripherally-released IL-6 
inducing other signalling molecules within cells of the BBB, which then penetrate into 
the brain to affect feeding.  Regardless of how peripherally-released IL-6 mediates 
anorexia and lethargy induced by s.c. administration of LPS it is evident that IL-6 is not 
the sole mediator of these responses.  Based on my finding that central administration of 
IL-1β decreased both voluntary exercise and food intake I hypothesized that endogenous 
brain IL-1β could possibly be involved in mediating lethargy and anorexia induced by 
local administration of LPS. 
 
To determine whether this indeed is the case, I specifically chose to antagonize the 
biological action of IL-1β in the brain by administering a caspase-1 inhibitor, which 
prevents the cleavage of pro-IL-β to biologically active IL-1β, i.c.v. (Chapter 4).  Others 
have reported that central administration of a caspase-1 inhibitor is an effective strategy 
to use for reducing IL-1β activity in the brain following systemic administration of LPS 
(Bilbo et al., 2005).  In my study I monitored the behavioural responses until the 
symptoms of sickness induced by LPS had ceased, so as to determine the cytokine 
involvement not only in the induction, but also in the resolution of these sickness 
responses.  I found that pre-treating rats with a caspase-1 inhibitor i.c.v. did not abolish 
the anorexia and lethargy induced by LPS, but it did significantly attenuate both the 
magnitude and the duration of the anorexia and lethargy induced by LPS.  Thus I have 
identified that endogenous brain IL-1β contributes to mediating lethargy and anorexia 
induced by local administration of LPS in rats.   
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While it has been established that administration of a caspase-1 inhibitor effectively 
reduces IL-1β activity in vivo following systemic administration of LPS (Bilbo et al., 
2005), I did not measure the concentration of IL-1β in the brain and therefore cannot 
confirm the extent to which i.c.v. administration of the caspase-1 inhibitor inhibited the 
synthesis of IL-1β in the brain.  It is therefore possible that if IL-1β was not completely 
inhibited by the dose of the caspase-1 inhibitor I injected, the contribution of endogenous 
brain IL-1β to mediating the anorexia and lethargy induced by s.c. administration of LPS 
I noted may be of a greater magnitude.   
 
The results I obtained with peripheral and central antagonism of endogenous IL-1β 
presented in chapter 2 and 4 appear to identify that brain, but not peripherally-released 
IL-1β plays an important role in mediating sickness behaviours induced by local 
administration of LPS.  My finding that IL-1β in the brain, but not IL-1β released in the 
periphery, contributes to mediating sickness behaviours appears to be at odds with the 
findings of others (Bluthé et al., 1992b).  Bluthé et al., (1992b) found that pre-treating 
rats with IL-1ra peripherally, but not centrally, attenuated the decrease in body mass and 
social exploration induced by systemic administration of LPS. 
 
Differences in the experimental design between my study and that of Bluthé et al., 
(1992b) may explain these contradictory findings.  Firstly, the difference noted with 
antagonism of peripherally-released IL-1β may have been related to the different route by 
which LPS was administered.  While the same dose of LPS (250 µg kg-1) was 
administered in both studies, I administered the LPS s.c. in my studies while they 
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administered LPS i.p in their study.  Injecting LPS s.c. appears to be a more 
representative experimental model of localized infection, than a model of systemic 
infection.  The lack of involvement of peripherally-released IL-1β I noted in mediating 
LPS-sickness behaviours may be related to s.c. administration of LPS not inducing 
sufficient IL-1β in the circulation, unlike the significant increase noted following i.p. 
administration of LPS (Bilbo et al., 2005), to influence the areas of the brain regulating 
these behaviours.  Secondly, the differences noted with antagonism of IL-1β in the brain 
may be related to the use of different substances to antagonize the biological action of 
endogenous brain IL-1β.  The time course of action of these two substances differs quite 
substantially, with IL-1ra being active for about 2 to 4 h (Bluthé et al., 1992b), while the 
caspase-1 inhibitor is active for at least 24 h (Rabuffetti et al., 2000).  Brain IL-1β has 
been shown to remain significantly elevated for prolonged periods of between 8 - 24 h 
following i.p. administration of LPS (Bilbo et al., 2005).  Thus in terms of investigating 
the involvement of endogenous brain IL-1β in mediating LPS-induced sickness 
behaviours, the longer period of IL-1β neutralization likely to be achieved with the 
caspase-1 inhibitor may have prolonged the inhibition of IL-1β in the brain and therefore 
produced the attenuated sickness behaviour responses noted in my study.   
 
It is also possible that the effects I noted following i.c.v administration of the caspase-1 
inhibitor may not be entirely specific to the action of IL-1β, but may also be related to the 
action of other pro-inflammatory cytokines, as the enzyme caspase-1 is not only involved 
in the processing of IL-1β, but is also involved in the processing of IL-18 and IL-33 
(Dinarello, 2005a). Administration of the capase-1 inhibitor may therefore have reduced 
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the synthesis of these two cytokines in addition to the synthesis of IL-1β in the brain.  
Even though as of yet the involvement of IL-18 and IL-33 in LPS-induced lethargy has 
not been identified, IL-18 has been implicated as a putative mediator of energy 
homeostasis by suppressing appetite (Zorrilla et al., 2007).  Thus the participation of 
these two cytokines in the biological processes described in my study cannot be excluded.  
 
Due to the strong likelihood that the contradictory findings regarding the peripheral 
involvement of IL-1β in mediating LPS-induced sickness behaviours may be related to 
the experimental model of infection used, systemic versus local, investigating the effect 
of endogenous antagonism of peripherally-released IL-1β following LPS administration 
via different routes (s.c., i.p., i.v. and i.m.) may provide clarity on the role of peripherally-
released IL-1β in mediating LPS-induced sickness behaviours.  Moreover, to identify if 
the failure to inhibit sickness behaviours induced by local and systemic administration of 
LPS following i.c.v. injection of IL-1ra (Bluthé et al., 1992b; Kent et al., 1992b) is 
indeed related to the short half-life of IL-1ra, it would be useful to investigate the effect 
of antagonism of endogenous brain IL-1β using IL-1ra and the caspase-1 inhibitor in the 
same study. 
 
In chapter 4 I also investigated the effect of antagonizing the biological action of 
peripherally-released IL-6 on the duration of the anorexia and lethargy induced by s.c. 
administration of LPS, as although peripherally-released IL-6 had been implicated in 
mediating LPS-induced sickness behaviours (Chapter 2 and Bluthé et al., 2000b), the 
extent to which its absence could facilitate recovery from LPS-induced sickness 
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behaviours had not been established.  In addition to my initial findings in chapter 2 which 
showed that treating rats with serum containing IL-6 antibodies attenuated the magnitude 
of anorexia and lethargy induced by s.c. administration of LPS, I identified in chapter 4 
that treating rats with serum containing IL-6 antibodies also facilitated a significantly 
faster recovery of the rats (by at least 2 days) from the suppressive effects of LPS on 
voluntary activity, food intake and growth.  Moreover, in chapter 4 I was able to 
demonstrate that the species-specific antiserum I administered did indeed significantly 
neutralize the LPS-induced bioactive IL-6 (by ~ 80%) in the plasma of the rats injected 
with LPS and the IL-6 antiserum.  Although I reduced the level of bioactive IL-6 in the 
circulation by a substantial margin it is likely that had I achieved complete neutralization 
the degree of attenuation I noted may have been of a greater magnitude.   
 
Although peripherally-released IL-6 appears to be an important endogenous mediator of 
anorexia and lethargy, how IL-6 released into the bloodstream from peripherally located 
immune cells influences the brain-mediated responses of anorexia and lethargy during a 
peripheral immune challenge however, remains unclear.  Others have reported that 
injecting LPS i.p. induces an increase in IL-1β mRNA in the brains of wild-type mice, 
however in IL-6 knockout mice the LPS-induced increase in IL-1β is greatly attenuated 
or entirely absent (Sparkman et al., 2006).  Thus, in the absence of IL-6, systemic 
administration of LPS failed to induce IL-1β in the brain.  Having identified in chapter 4 
that brain IL-1β is involved in mediating anorexia and lethargy induced by local 
administration of LPS, one mechanism by which peripherally-released IL-6 could be 
mediating anorexia and lethargy is via the induction of IL-1β in the brain.  The possibility 
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that IL-6 can induce the synthesis of IL-1β is intriguing as the vast majority of the 
literature points towards IL-1β inducing IL-6 and not vice versa (Shalaby et al., 1989; 
Sironi et al., 1989; Schindler et al., 1990). 
 
Not only did I identify an important role for peripherally-released IL-6 in mediating 
anorexia induced by local administration of LPS in my thesis, but I confirmed the 
importance of another endogenous mediator, leptin (chapter 2).  Treating rats peripherally 
with leptin antiserum abolishes the anorexia induced by s.c. administration of LPS.  
Using the same species-specific leptin antiserum, but administered at a lower dose, others 
have demonstrated an attenuation of anorexia induced by i.p. administration of LPS in 
rats (Sachot et al., 2004).  In contrast, studies investigating the involvement of leptin in 
mediating LPS-induced anorexia using rats with defective receptor-mediated transport 
and intracellular signalling of leptin, have shown that leptin signalling does not appear to 
influence LPS-induced anorexia (Faggioni et al., 1997; Lugarini et al., 2005).  There are 
two likely explanations for the discrepancies noted between studies using rats with 
genetic defects in the leptin system and leptin antiserum.  Firstly, due to the importance 
of food intake for survival, the control of food intake is not solely dependent on a single 
pathway, but rather is regulated by different pathways involving mediators other than 
leptin, such as cholecystokinin, insulin and glucagon.  Thus it is possible that the absence 
of the leptin-mediated pathway occurring early on in the development of mutant animals 
may result in other pathways involved in food intake homeostasis compensating.  These 
alternative pathways could be activated during pathological conditions like LPS 
stimulation, leading to the observed anorexia in animals with genetic defects in the leptin 
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system.  Secondly, systemic administration of LPS has been shown to induce comparable 
concentrations of IL-6 in the circulation of leptin-deficient (ob/ob) mice and their 
respective lean littermates (+/?ob mice) (Faggioni et al., 1999).  Thus humoral mediators 
other than leptin, such as IL-6 identified in this thesis, may compensate for the absence of 
leptin in animals with genetic defects in the leptin system (Sachot et al., 2004).  My 
finding that peripherally-released leptin and peripherally-released IL-6 appear to share 
the same biological effect of suppressing food intake following s.c. administration of 
LPS, may be related to them both: (i) belonging to the same long-chain helical cytokine 
family and sharing a common signal transducer among their receptors (Zhang et al., 
1994; Vaisse et al., 1996) or (ii) inducing the same important downstream mediator of 
food intake, IL-1β, in the brain (Sachot et al., 2004). 
 
Not only do leptin and IL-6 released in the periphery both appear to be involved in 
mediating the suppression of food intake following s.c. administration of LPS, but they 
also both appear to be involved in mediating the fever response, as treating rats 
peripherally with either leptin antiserum or IL-6 antiserum abolishes fever induced by s.c. 
administration of LPS (Chapter 2).  The involvement of both peripherally-released leptin 
and peripherally-released IL-6 in mediating LPS-induced fever may be related to 
similarities in the actions of the two cytokines, as they both have been shown to induce 
COX-2, an important downstream mediator of fever, in the brain (Rummel et al., 2006; 
Inoue et al., 2006).  The involvement of leptin in mediating LPS-induced fever may 
however not only be related to the induction of COX-2 in the brain, but it also may be 
related to the activation of thermoeffectors required for fever production, in particular the 
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activation of metabolic heat production.  Leptin raises metabolic heat production by 
increasing sympathetic outflow to brown adipose tissue (nonshivering thermogenesis) in 
small rodents (Collins et al., 1996).  It is unlikely however that the attenuated effects I 
noted on fever production following administration of leptin antiserum were related to 
blocking the thermogenic action of leptin, as leptin appears to have a critical role in 
chronic, but not acute activation of thermogenesis (Girardier et al., 1995; Steiner & 
Romanovsky, 2007) and fever is brought about by acute activation of thermoeffectors 
(Romanovsky et al., 2005).  Moreover, in a thermally neutral environment activation of 
thermogenesis may not be a prerequisite to increase core body temperature during fever, 
as the increase in core body temperature may be achieved by constriction of skin vessels 
alone (Romanovsky et al., 2002). It therefore appears that the participation of leptin in 
LPS-induced fever is mostly related to its inflammatory action in the brain. 
 
5.2 Differences in the cytokine-mechanisms mediating fever and sickness behaviour  
 
Not only did I investigate the contribution of endogenous cytokines in mediating LPS-
induced sickness behaviours in the studies presented in this thesis, but I also investigated 
their contribution in mediating fever induced by s.c. administration of LPS.  My rationale 
for concurrently investigating the contribution of endogenous cytokines in mediating 
sickness behaviours and fever was to identify possible differences in the cytokine-
mechanisms mediating these responses.  The observation I made in chapter 4 and which 
others have also made previously (Hübschle et al., 2006), that sickness behaviours 
continue for a longer period of time than does fever during infection/inflammation, has 
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lead to the speculation that the cytokine-mechanisms regulating fever and sickness 
behaviours may not be the same (Kent et al., 1992a; Dantzer, 2001). 
 
In the studies presented in this thesis I uncovered some distinct differences in the 
cytokine-mechanisms regulating fever and sickness behaviours.  For instance, LPS-
induced fever could be abolished by inhibiting the action of peripherally-released IL-6, 
while it appeared that LPS-induced lethargy and LPS-induced anorexia could be 
abolished only if both endogenous brain IL-1β and peripherally-released IL-6 were 
inhibited (chapter 4).  Moreover, central administration of the lowest dose of IL-1β or IL-
6 decreased voluntary activity in rats in the absence of fever (chapter 4).  These 
differences highlight that: (i) brain-intrinsic cytokines may be more important in 
mediating sickness behaviours and they are in mediating fever and (ii) the brain sites 
controlling sickness behaviours, in particular lethargy, may be more sensitive to the 
presence of cytokines than the brain sites controlling temperature.  Both of these 
differences are likely to account for the prolonged duration of the sickness behaviours 
during illness.  From a clinical point of view identifying the cause for the longer duration 
of sickness behaviours is particularly relevant, as it is the prolonged duration of the 
sickness behaviour responses that are most disabling and uncomfortable for patients to 
endure during illness (Bower et al., 2002; Hewlett et al., 2005).  Moreover, having a 
better understanding of the physiological mechanisms inducing both fever and sickness 
behaviours such as anorexia and lethargy, may provide clinicians with more insight into 
managing not only the thermal but also the non-thermal responses to infection. 
 
 144 
5.3 Clinical implications and recommendations 
 
My finding in chapter 4 that reducing either the amount of biologically active IL-6 in the 
circulation or IL-1β in the brain significantly enhances the resolution of anorexia and 
lethargy by at least two days in rats, but does not completely prevent these sickness 
behaviours from occurring, appears to indicate the complexity of the cytokine 
involvement in mediating these two sickness behaviours during a localized Gram-
negative bacterial infection.  Using similar experimental tools, others (Swiergiel & Dunn, 
1999) have also noted this trend of multiple cytokine involvement in mediating sickness 
behaviours during a systemic Gram-negative bacterial infection.  Therefore while 
individual cytokines, such as IL-6 and IL-1β, are possible targets for therapies aimed at 
alleviating anorexia and lethargy in patients with bacterial infections, it appears that to 
abolish the presence of sickness behaviours multiple cytokines may need to be targeted.   
 
Pro-inflammatory cytokines also perform important immune functions, however which 
facilitate pathogen elimination.  They increase the microbial activity of phagocytic cells, 
activate adjacent epithelium tissues which result in the attraction of neutrophils and 
monocytes and induce the production of acute phase proteins by the liver (Kapetanovic & 
Cavaillon, 2007).  Therefore, while inhibiting the action of multiple cytokines may 
resolve the sickness responses quicker, this action could possibly compromise the ability 
of the host to fight infection in the situation of a live, replicating pathogen.  In instances 
of chronic infection where patients are placed on prolonged treatment regimens, 
inhibiting the action of cytokines may increase the prevalence of opportunistic infections.  
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Selectively inhibiting the downstream mediators by which cytokines induce sickness 
behaviours may prove to be a better tool therapeutically, as that could preserve the 
actions of pro-inflammatory mediators required for pathogen elimination yet improve the 
malaise and sense of sickness in the patient.  To therefore identify the most beneficial 
treatment strategy for sickness behaviours in patients, future pathophysiological 
mechanism-based assessment studies of sickness behaviours in animal models of 
infection/inflammation are needed which not only look at specific cytokines, but also the 
activation status of their intermediate signalling pathways and their downstream products 
(Dantzer et al., 2008).   
 
Although the results presented in this thesis have important implications for the treatment 
of patients with bacterial infections, they may not be directly transferable to medially ill 
patients in general, as the cytokine profiles induced by different pathogens is not 
necessarily the same.  The high prevalence of non-specific behavioural symptoms in 
medically ill patients not only with a “common cold” or flu, but also in patients with 
some of the most harmful, costly and debilitating diseases currently experienced in the 
Western World: coronary heart disease, cancer, obesity, type II diabetes and 
neurodegenerative disorders associated with aging (Dantzer et al., 2008) necessitates the 
continuation of preclinical studies, such as those presented in this thesis to be carried out 
using established animal models of disease, to identify possible therapies for these 
symptoms in patients. 
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Not only does the work I have presented in this thesis have value in terms of identifying 
possible targets for the treatment of symptoms of medically ill patients, but it also may be 
of value in improving our approach to identifying and monitoring infection/inflammation 
in patients.  From early on in the history of medicine, fever has been viewed by 
physicians and patients alike as the principal symptom of illness and thus decisions 
concerning the onset of and recovery from illness were primarily based on a patient’s 
body temperature.  The findings presented in this thesis showing that fever is outlasted by 
both the period of lethargy and anorexia in the presence of a simulated Gram-negative 
bacterial infection in rats, indicates that the behavioural symptoms associated with 
infection, such as lethargy and loss of appetite, should become part of the close 
monitoring of the condition of patients, as the presence of these sickness behaviours, may 
in fact be a more valuable clinical marker of illness and recovery in patients, than is body 
temperature alone. 
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